2025
ANNUAL REPORT

CSI SINGAPORE

CONTENTS

1

Introduction

2025 – Advancing Discovery, Deepening Impact

2025 - Advancing Discovery, Deepening Impact

2025 was a year of steady progress and growing impact for the Cancer Science Institute of Singapore (CSI Singapore). Building on strong scientific foundations, we continued to advance fundamental discovery while strengthening pathways that translate research into meaningful clinical and societal outcomes - —driven by our strong scientific leadership, meaningful collaborations, and a shared commitment to rigor and purpose.
Throughout the year, our researchers pursued innovative, multidisciplinary approaches to deepen understanding of cancer initiation, progression, and therapeutic response. Together, these integrated efforts yielded new insights into cancer risk, uncovered therapeutic vulnerabilities, and informed more precise and effective treatment strategies. The strength and quality of our work are reflected in a robust portfolio of publications in leading scientific journals, as well as in the recognition of excellence our scientists and students have received through highly competitive awards and honours.

Several research breakthroughs in 2025 highlight the impact of CSI Singapore's work. A Phase 2 clinical trial showed that a novel drug combination significantly improved tumour response in patients with recurrent or advanced nasopharyngeal cancer, offering renewed hope for those with limited treatment options. In parallel, a multidisciplinary collaboration between researchers in Singapore and the United States uncovered new insights into how the breast cancer gene BRCA2 protects the genome during cell division—advancing understanding of early cancer development across multiple organs and pointing towards new approaches for cancer treatment.

Collaboration remained a cornerstone of CSI Singapore's mission in 2025. Through sustained partnerships with national and international institutions, we at CSI Singapore fostered an environment where ideas, expertise, and technologies converge to accelerate discovery. The CSI Singapore-Kyoto University Joint Symposium in November 2025 exemplified this collaborative ethos, reinforcing long-standing institutional ties and strengthening scientific exchange across disciplines, while laying the groundwork for future joint research initiatives. Together, these joint endeavours reflect the essence of modern cancer science—deeply interdisciplinary, globally connected, and united by a shared commitment to advancing human health.

As the global cancer burden continues to rise, driven by ageing populations and evolving environmental and lifestyle factors, the need for deeper biological insight and more effective therapeutic strategies has never been more urgent. In this landscape, CSI Singapore plays a pivotal role in advancing cancer research across the full continuum—from fundamental discovery science to translational and clinical investigations. CSI Singapore is committed to generating new knowledge, accelerating the development of improved diagnostics and therapies, and shaping solutions that will meaningfully impact cancer prevention and patient care worldwide. Together, through these efforts, CSI Singapore remains committed to shaping a future where cancer is better understood, driving discoveries that aim to transform the future of cancer prevention, diagnosis, and treatment.

2

The Year in Numbers

A. Core Facilities

Flow Cytometry Core

Flow Cytometry Core (FACS)

Erica XU/Rex NG

Genomics and Data Analytics Core

Genomics and Data Analytics Core (GeDAC)

Jason PITT

Spatial Biology Core

Spatial Biology Core (SBC)

Patrick William JAYNES

Quantitative Proteomics Core

Quantitative Proteomics Core (QPC)

Dennis KAPPEI

Transgenic & Gene Targeting Facility

Transgenic and Gene Targeting Facility (TGTF)

Yvonne TAY

B. Staff Strength



C. Publication Highlights

120 Publications

100 International Collaborations

26 Press Releases

64,747 Citations Received (2011-2025)

9 Highly Cited Papers

Cumulative Publications Based on IF Score



D. Collaboration Network

2025 Top Collaborators by Country

1. United States
2. China
3. Japan
4. United Kingdom
5. Germany
6. South Korea
7. Australia
8. Italy
9. Canada
10. Malaysia

3

The Year in Research

A. Research Spotlights

BRCA2 C-terminal Clamp Restructures RAD51 Dimers to Bind B-DNA for Replication Fork Stability (Molecular Cell, May 2025)

The breast cancer gene BRCA2 works to suppress cancers of the breast, ovaries, pancreas and prostate. Families who carry a faulty mutant copy of this gene are therefore at a high risk of developing these cancers. New research from Prof. Ashok Venkitaraman's lab at the CSI Singapore sheds new light into how BRCA2 acts to suppress carcinogenesis, with implications for cancer prevention and therapy. In earlier research, it was discovered that the breast cancer gene, BRCA2 normally works to safeguard the human genome, by repairing broken DNA, and by protecting replicating DNA during cell division.

However, how the gene performs these distinct roles has long remained unclear. Now, in collaboration with researchers from the MD Anderson Cancer Center (USA) and National University of Singapore, Prof. Venkitaraman's team has identified a key mechanism by which BRCA2 protects DNA as it replicates. Their findings reveal that a flexible "hinge" within the BRCA2 protein enables it to reorient the enzyme RAD51 into a specific shape necessary to shield DNA strands encountering stress during replication. Their research not only illuminates how our genome is safeguarded during cell division, but also how cancer may arise when this safeguarding mechanism fails.

Aggressive B Cell Lymphomas Retain ATR-Dependent Determinants of T Cell Exclusion from the Germinal Center Dark Zone (Journal of Clinical Investigation, July 2025)



A study published in The Journal of Clinical Investigation, led by scientists including, Dr. Anand Jeyasekharan from CSI Singapore, investigated why aggressive germinal-center B cell lymphomas exhibit evasion of anti-tumor immunity. They discovered that these tumors retain a gene expression program resembling the germinal center dark zone, which is naturally devoid of T cells, and that this program is linked to ATR-dependent DNA damage response activity and suppression of inflammatory signaling, contributing to T cell exclusion from the tumor microenvironment — a key immune-evasion mechanism that may inform future strategies to enhance immunotherapy in diffuse large B cell lymphoma.

B. Investigative Reports

Novel Drug Combination Spells Hope for Patients with Nasopharyngeal Cancer

A clinical trial in Singapore that aims to offer patients with recurrent or advanced nasopharyngeal cancer a new treatment option has shown promising results. Medical literature has shown that when this group of patients are treated with chemotherapy drugs that contain the metal platinum, up to six in 10 will see their cancer shrink or disappear. Most of these patients will eventually relapse, and together with those who have platinum-resistant disease, they face a poor prognosis with cancer progression typically occurring within four to six months.

A new study, published in medical journal The Lancet Oncology on 15 January 2025, has shown that a drug cocktail of pembrolizumab and bevacizumab produced significantly higher response rate than if patients were given only pembrolizumab. Pembrolizumab, a type of immunotherapy drug, targets and blocks a protein called PD-1 on the surface of certain immune cells. Blocking PD-1 triggers the immune cells to find and kill cancer cells. On the other hand, bevacizumab works by blocking a protein called vascular endothelial growth factor (VEGF), which nasopharyngeal cancer cells produce in large amounts, resulting in complex disordered microscopic blood vessels. Blocking VEGF can restore order in these microscopic blood vessels and promote movement of immune cells into the cancer. In the phase 2 trial of 48 patients, half of them were randomly assigned to pembrolizumab, while the other half received both pembrolizumab and bevacizumab. These patients were recruited from the National University Hospital, the National University Cancer Institute, Singapore (NCIS) and Tan Tock Seng Hospital.

The team also collaborated with investigators from the CSI Singapore at the National University of Singapore (NUS) and Genome Institute of Singapore to analyse tumour and blood samples of patients in the study. After a median follow-up of 28 months, the researchers found that more than half, or 58.3 per cent, of the patients who received the drug combination had their cancer shrink or disappear, compared with only 12.5 per cent of patients who were given the single drug. The median progression-free survival was 13.8 months in the combination drug group versus 1.6 months in the single drug group. The researchers hail this as the first randomised controlled trial to compare the combination treatment regimen of anti-VEGF (bevacizumab) and anti-PD-1 (pembrolizumab) drugs with just an anti-PD-1 drug in nasopharyngeal cancer. More than a third of patients in both groups were previously treated with two or more types of chemotherapy drugs. What was noteworthy was that patients who progressed on the pembrolizumab-only group were allowed to crossover to the combination group, and a third of these patients achieved significant tumour reduction after the crossover.

Prof. Goh Boon Cher, Deputy Director at CSI Singapore, NUS, said: "Currently, immunotherapy alone does not activate an adequate immune response to shrink nasopharyngeal cancer that has spread. This study showed that priming the cancer with another drug bevacizumab, before the use of pembrolizumab, induces strong changes in the surrounding non-cancerous cells that support the cancer environment. This leads to a much stronger and sustained control of cancer and can potentially be a practice-changing advancement in treatment."

Prof. Goh, who is also Deputy Director (Research) and Senior Consultant, Department of Haematology-Oncology, NCIS, and Dr. Chong Wan Qin, Consultant, Department of Haematology-Oncology, NCIS, are lead investigators of the study. Dr. Chong said: "Patients with recurrent or metastatic nasopharyngeal cancer, who have exhausted standard treatment options, face a particularly challenging prognosis. Our findings highlight the synergistic potential of combining immunotherapy (pembrolizumab) with anti-angiogenic therapy (bevacizumab). This drug combination is generally well-tolerated and offers patients a meaningful extension in progression-free survival, along with an improved quality of life." Nasopharyngeal cancer forms in the tissues of the nasopharynx, or upper part of the throat behind the nose. It is the third most common cancer among men aged 30 to 49 in Singapore, according to the Singapore Cancer Registry Annual Report 2022.

The team's significant findings were published in The Lancet Oncology (15 January 2025):
https://doi.org/10.1016/S1470-2045(24)00677-6
and shared on Research News on
https://medicine.nus.edu.sg/trp/n2cr/efficacy-of-combined-pembrolizumab-and-bevacizumab-in-platinum-resistant-nasopharyngeal-carcinoma/



Magnetic resonance imaging of a patient with tumour in the nasopharynx (arrowed) that regressed on experimental arm treatment and completed 2 years treatment on the trial .

New Breakthrough Combats Lenalidomide Resistance in Multiple Myeloma



A new study conducted by researchers from CSI Singapore at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance in multiple myeloma (MM), offering new insights into potential strategies for improving treatment outcomes and overcoming drug resistance.

The team, led by Dr. Teoh Phaik Ju and Dr. Koh Mun Yee, together with Prof. Chng Wee Joo and A/Prof. Polly Chen, identified a gene called ADAR1, which encodes an RNA editing enzyme, as a key factor in suppressing the immune response triggered by lenalidomide—an immune-stimulating drug, essential to kill MM cells.

MM is a type of cancer that affects plasma cells in the bone marrow. While standard-of-care treatments like lenalidomide, an immunomodulatory drug (IMiD), have improved survival rates for many MM patients, a significant number still experience relapse due to the development of drug resistance.

Lenalidomide works by binding to a protein called cereblon (CRBN), which breaks down several proteins that are essential for MM cell survival and growth. However, many patients eventually stop responding to the drug, leading to disease relapse. While 20 to 30 per cent of the resistance cases have been linked to defects in CRBN and its associated factors, the underlying mechanisms in most resistance cases have remained poorly understood. This study reports new findings demonstrating that ADAR1 abnormalities lead to a suppressed immune system in IMiD-resistant MM cases.

ADAR1 inhibits lenalidomide's activity by editing double-stranded RNA (dsRNA), thus hindering the immune response and reducing the effectiveness of the drug in combating MM growth and proliferation. The researchers discovered that by reducing the levels of ADAR1 and increasing dsRNA accumulation in MM cells, they could increase the sensitivity of the cells to lenalidomide. This would, in turn, lead to the activation of the immune responses and kill the MM cells. The discovery adds a new layer to the understanding of how MM patients may become resistant to IMiD, highlighting the role of dsRNA pathways beyond the previously understood CRBN pathway.

The findings also suggest that targeting ADAR1 and the dsRNA pathway could offer promising strategies to overcome resistance to lenalidomide in MM. As clinical trials continue to explore the potential of new IMiD analogues, such as CRBN-E3 ligase modulators (CELMoDs) and other drugs with similar pharmacological profile, combining these treatments with ADAR1 inhibitors may provide a more effective approach to tackle drug resistance and improve patient outcomes.

With ADAR1 inhibitors currently in preclinical development, this strategy holds great promise for advancing treatment options for MM. In addition, the research team plans to further investigate ADAR1's role in alternative splicing, a post-transcriptional gene regulatory mechanism, in MM, which could uncover even more opportunities for treatments.

The findings were published in the scientific journal Blood on 13 March 2025 https://doi.org/10.1182/blood.2024024429 and shared on NUS News: https://news.nus.edu.sg/combating-lenalidomide-resistance-in-multiple-myeloma/

New Breakthrough Combats Lenalidomide Resistance in Multiple Myeloma



A new study conducted by researchers from CSI Singapore at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance in multiple myeloma (MM), offering new insights into potential strategies for improving treatment outcomes and overcoming drug resistance.

The team, led by Dr. Teoh Phaik Ju and Dr. Koh Mun Yee, together with Prof. Chng Wee Joo and A/Prof. Polly Chen, identified a gene called ADAR1, which encodes an RNA editing enzyme, as a key factor in suppressing the immune response triggered by lenalidomide—an immune-stimulating drug, essential to kill MM cells.

MM is a type of cancer that affects plasma cells in the bone marrow. While standard-of-care treatments like lenalidomide, an immunomodulatory drug (IMiD), have improved survival rates for many MM patients, a significant number still experience relapse due to the development of drug resistance.

Lenalidomide works by binding to a protein called cereblon (CRBN), which breaks down several proteins that are essential for MM cell survival and growth. However, many patients eventually stop responding to the drug, leading to disease relapse. While 20 to 30 per cent of the resistance cases have been linked to defects in CRBN and its associated factors, the underlying mechanisms in most resistance cases have remained poorly understood. This study reports new findings demonstrating that ADAR1 abnormalities lead to a suppressed immune system in IMiD-resistant MM cases.

ADAR1 inhibits lenalidomide's activity by editing double-stranded RNA (dsRNA), thus hindering the immune response and reducing the effectiveness of the drug in combating MM growth and proliferation. The researchers discovered that by reducing the levels of ADAR1 and increasing dsRNA accumulation in MM cells, they could increase the sensitivity of the cells to lenalidomide. This would, in turn, lead to the activation of the immune responses and kill the MM cells. The discovery adds a new layer to the understanding of how MM patients may become resistant to IMiD, highlighting the role of dsRNA pathways beyond the previously understood CRBN pathway.

The findings also suggest that targeting ADAR1 and the dsRNA pathway could offer promising strategies to overcome resistance to lenalidomide in MM. As clinical trials continue to explore the potential of new IMiD analogues, such as CRBN-E3 ligase modulators (CELMoDs) and other drugs with similar pharmacological profile, combining these treatments with ADAR1 inhibitors may provide a more effective approach to tackle drug resistance and improve patient outcomes.

With ADAR1 inhibitors currently in preclinical development, this strategy holds great promise for advancing treatment options for MM. In addition, the research team plans to further investigate ADAR1's role in alternative splicing, a post-transcriptional gene regulatory mechanism, in MM, which could uncover even more opportunities for treatments.

The findings were published in the scientific journal Blood on 13 March 2025: https://doi.org/10.1182/blood.2024024429 and shared on NUS News: https://news.nus.edu.sg/combating-lenalidomide-resistance-in-multiple-myeloma/

AI Tool Predicts Chemotherapy Response from Routine Cancer Gene Tests, Paving the Way for Personalised Treatment and Drug Repurposing in Refractory Cancer

Researchers from the Cancer Science Institute of Singapore (CSI Singapore), the National University of Singapore (NUS), and the National University Cancer Institute, Singapore (NCIS) have developed an artificial intelligence model, DruID (Drug Identifier), that predicts how cancer patients may respond to chemotherapy using genomic sequencing data already produced during routine clinical care, enabling predictive insights without the need for additional assays, funding, or extra patient procedures.

This collaborative effort brought together computational scientists and clinical oncologists, including CSI Singapore Principal Investigators Dr. Anand Jeyasekharan, Dr. Jason Pitt, and A/Prof. David Tan, bridging data science and clinical oncology to develop predictive models applicable to real-world patient datasets. Published in iScience, the study marks an important step toward more personalised and effective cancer treatment by leveraging data already generated in routine clinical care.

Next-generation sequencing (NGS) is widely used in oncology to identify tumour mutations. However, only a small proportion of patients have mutations that can be matched to approved targeted therapies. Consequently, many patients receive chemotherapy without clear genomic guidance, and treatment options become limited if their cancer no longer responds.

Unlike earlier artificial intelligence models that rely on large-scale genomic datasets rarely available in standard practice, DruID is designed to work with mutation data derived from focused NGS panels commonly used in hospitals. Using this clinically accessible data, DruID outperformed existing machine learning approaches in predicting chemotherapy response. The model was trained on both laboratory and patient datasets, applying advanced learning strategies to identify patterns across different data sources and enhance predictive accuracy. Validation in Singapore patient cohorts further demonstrated its relevance and robustness in real-world clinical settings. DruID's predictive capability may also support the repurposing of existing drugs for patients with hard-to-treat cancers.

Now undergoing evaluation in a prospective clinical trial in Singapore, DruID will continue to be refined through tumour-specific models, combination therapy predictions, and improved interpretability. This research underscores CSI Singapore's commitment to harnessing advances in artificial intelligence and data science to address clinically meaningful challenges. By integrating computational innovation with cancer genomics and translational oncology within the NUS-NUH ecosystem, the study aligns with Singapore's Precision Medicine initiatives and national AI strategy under RIE 2030, advancing personalised cancer care and strengthening Singapore's position in AI-enabled biomedical innovation.

The study, titled "A multi-task domain-adapted model to predict chemotherapy response from mutations in recurrently altered cancer genes," is published in the journal iScience and available on https://doi.org/10.1016/j.isci.2025.111992 21 March 2025



New Hybrid AI Framework Advances Protein Structure Prediction

In a significant advance for AI-driven structural biology, a study published in Nature Biotechnology , led by CSI Singapore Senior Principal Investigator, Prof. Yang Zhang, introduces D-I-TASSER, an innovative hybrid deep-learning and simulation framework that establishes a new benchmark in protein structure prediction. By integrating artificial intelligence-derived features with physics-based folding simulations, the approach enhances both structural accuracy and applicability, particularly for proteins that remain challenging for existing prediction methods.

D-I-TASSER significantly outperformed traditional and leading AI models, including AlphaFold2 and AlphaFold3, in predicting both single-domain and complex multidomain protein structures — a longstanding challenge in structural biology. Independent benchmarking, including performance in the CASP15 assessment, demonstrated broader coverage and improved structural precision across diverse protein datasets.

Accurate protein structure prediction is foundational to drug discovery, therapeutic target identification, and biomarker development. Applied at proteome scale, the framework generated high-confidence structural models for a large proportion of human proteins, creating a valuable resource for the global biomedical research community. By making the code and datasets openly available, the team has enabled wider scientific adoption and downstream translational applications.

“Beyond improving the accuracy of AI-based protein structure prediction, D-I-TASSER introduces a hybrid framework that combines physics-based folding principles with deep learning,” said Prof. Yang Zhang. “This integration offers a new way to model the dynamic folding process of proteins, helping to open the ‘black box’ of AI predictions and providing valuable insights for next-generation structure-based drug discovery.”

This work reflects CSI Singapore’s commitment to advancing cutting-edge artificial intelligence research that supports biomedical innovation. By integrating computational excellence with physical and biological insights, the study contributes to Singapore’s broader ambitions in AI-enabled life sciences and precision medicine, reinforcing the nation’s position as a hub for impactful, technology-driven research.

The study, titled "Deep-learning-based single-domain and multidomain protein structure prediction with D-I-TASSER," is published in the journal nature Biotechnology on 23 May 2025 and available at: https://doi.org/10.1038/s41587-025-02654-4



C. Welcome to Our New PIs

Jiangbo Wei

What appealed to you about CSI Singapore?

I’m drawn to CSI Singapore for its welcoming, professional environment where colleagues are supportive, collaborative, and a pleasure to work with. I’m especially grateful to Polly, who helped me find my footing in both the local RNA community and at CSI. Importantly, the Director’s visionary leadership sets a clear, ambitious trajectory for the institute, which is deeply inspiring. I’m particularly excited by CSI’s strong emphasis on RNA biology, which aligns closely with my scientific interests and expertise. Finally, the institute’s culture and infrastructure enable meaningful collaborations, both within CSI and with clinical partners, creating real opportunities to translate discoveries into impact.

How has the shift been from University of Chicago to an Assistant Professor at CSI Singapore?

The transition from UChicago to Assistant Professor in Chemistry and DBS and investigator at CSI Singapore has been both challenging and rewarding. During my PhD and postdoc, I spent eight years with Prof. Chuan He, my role model, whose mentorship shaped my scientific rigor, curiosity, and collaborative ethos, and continues to guide how I lead a group. Moving into group leadership brought new responsibilities and was difficult at first, but with guidance from senior colleagues I have grown more confident and effective.

My joint appointment reflects an interdisciplinary background. Alongside running a research program, I teach, and while course preparation was demanding in the first year, it helped me learn, organize, and communicate complex ideas more clearly, and broaden my perspective beyond daily experiments. This role also offers a special opportunity to connect chemists with cancer biologists. I aim to serve as a bridge by bringing chemical tools into cancer biology and translating biological questions into tractable chemical problems to catalyze collaboration and accelerate discoveries. I am grateful to all the senior colleagues whose support has made this transition smooth.

What are you most excited to work on/working on at CSI Singapore?

I am most excited to elucidate context-dependent gene regulation mediated by epitranscriptomics/epigenetic mechanisms. In the cancer context, my lab investigates how epitranscriptomics/epigenetic mechanisms drive drug resistance and define synthetic lethal relationships between epitranscriptomics/epigenetic mechanisms and key signaling pathways or external stimuli. In parallel, my lab is developing chemical biology tools to profile and manipulate features of RNA and RNA modification with high precision. These RNA centered approaches may enable systematic discovery of vulnerable nodes in cancer cells and reveal actionable mechanisms. Ultimately, I hope to translate these insights into biomarkers and therapeutic strategies in collaboration with colleagues and clinicians at CSI Singapore.

What's your most "this could only happen in science" moment?

An unforgettable "only in science" moment is when results defy the original hypothesis but ignite a better one that leads to a more impactful discovery. What looks like failure transforms into success: a puzzling artifact becomes a testable hypothesis, a collaboration, and a path to potential translation. The convergence of curiosity, rigor, and serendipity to open an unforeseen line of inquiry is, to me, quintessentially scientific.

If your research were a hawker dish, what would it be and why?

Economy Rice, or cai png. My research looks like a tray of seemingly ordinary dishes, but when you pair them well, it becomes something surprisingly memorable. I work across chemical biology, RNA biology, epigenetics, and cancer, mixing tools and ideas to suit the question at hand, much like choosing the right combination of meats and vegetables for the day. The strength is in thoughtful integration: the right pairing of methods/models and more importantly, collaboration, can reveal mechanisms of epigenetics/epitranscriptomics centered regulation, and deliver outcomes that are greater than the sum of their parts.

Yang Li

What appealed to you about CSI Singapore?

First of all, Singapore is a great place to do research, the system is efficient, and the environment for education and science is very strong. CSI combines both basic biology and translational research, which I think is very important for applying AI to real biomedical problems. Also, CSI focuses a lot on RNA biology and structural studies, which matches well with my background. And finally, CSI is simply the best place to do this kind of research.

How has the shift been from a Research Scientist to a Special Fellow at CSI Singapore?

At first, I felt very excited. Previously as a Research Scientist, I was mainly focused on the research itself, developing models, analysing data, and writing papers. Now, as a Special Fellow, I have the opportunity to lead my own projects which I have always looked forward to. Later on, I also started to feel the challenges, such as mentoring students, managing collaborations, and applying for grants. It is a big step, but I know this is something that I have to go through sooner or later. So why not now?

What are you most excited to work on/working on at CSI Singapore?

I will be most excited about building (perhaps) next-generation AI models that can model the interaction patterns between macromolecules at atomic resolution. I also look forward to working together with researchers at CSI to apply these models to real problems in cancer biology and drug discovery.

What's your most "this could only happen in science" moment?

Probably the time when we trained a deep learning model on existing protein structures, and it started predicting accurate structures that matched experimental results, even when the sequence was very different from any known ones. That moment really showed me the power of AI in structural biology. But that was more than five years ago, and I hope to experience an even more exciting moment soon during my time at CSI

If you could name a cancer gene after a Singlish phrase, what would it be?

I don't know much about genes, but maybe I would just add "lah" after their official names. It makes them sound more Singaporean and fun.

If your research were a hawker dish, what would it be and why?

I think it would be zacaifan (杂菜饭), or economy rice. My research mixes many different ingredients like protein, DNA, RNA, and small molecules, just like zacaifan. I use AI to model them all together, and you can easily customise the combination depending on the biological question or application. It's flexible and affordable.

Yilong Zhou

What appealed to you about CSI Singapore?

I was drawn to CSI Singapore for its global reputation in cancer biology, vibrant research environment, and strong emphasis on collaboration between basic scientists and clinician-scientists. The institute's focus on RNA biology closely aligns with my interests, and the vision of Professor Venkitaraman to build Asia's leading cancer center is deeply inspiring. With close ties to NUS Centre for Cancer Research (N2CR), CSI offers an ideal setting to integrate my immunology background into translational cancer research.

How has the shift been from a postdoc at MaxPlanck Institute in Germany to an Assistant Professor at CSI Singapore?

The transition from a postdoc at Max Planck to an Assistant Professor at CSI Singapore has been both exciting and challenging. As a postdoc, I focused solely on research, whereas now I juggle multiple roles—research, teaching, mentoring, and grant writing. While the learning curve has been steep, these new responsibilities have enriched my perspective and strengthened my science. Teaching courses aligned with my research interests, like tumor biology and RNA biology, has been especially rewarding. I'm also grateful for the strong support from the CSI and NUS community, which has made the transition much smoother.

What are you most excited to work on at CSI Singapore?

My group is focused on uncovering RNA damage-driven mechanisms that enable cells to adapt to stress, particularly within the hostile tumour microenvironment before and after therapy. Understanding how processes like stress granule formation help cancer cells survive, and resist treatment is a novel and exciting area. With the advanced technologies I have developed and been trained in, I believe we are well-positioned to tackle these questions. Ultimately, we hope our discoveries will open new avenues for therapeutic intervention.

What's your most "this could only happen in science" moment?

I had set out to treat cells with UV, expecting the classic DNA damage response. But to my surprise, DHX9 — a nuclear RNA helicase — escaped into the cytoplasm and formed strange, patchy foci. At first, everyone thought the experiment had failed. But out of sheer curiosity, I stained for G3BP1, a known stress granule marker. To my astonishment, it lit up those odd foci like fireworks. That unexpected moment sparked a cascade of follow-up experiments, which ultimately led to the identification of a novel RNA damage-induced condensate — a structure clearly distinct from canonical stress granules. What began as a routine DNA damage experiment turned into a new chapter in RNA stress biology.

If you could name a cancer gene after a Singlish phrase, what would it be?

I named it SiaRBP1 because I'm studying an RNA-binding protein (RBP) that, surprisingly, plays a key role in controlling cancer chemotherapy resistance. The name reflects both its function—stress-induced adaptive RNA regulation—and adds a touch of Singlish flair, since cancer cells under genotoxic stress really do go 'Sia!' to survive.

If your research were a hawker dish, what would it be and why?

If my research were a hawker dish, it would be laksa—rich, complex, and layered. Like laksa's blend of coconut, spice, and umami, my research mixes different "flavours" of biology, DNA damage, RNA damage, phase separation, post-translation modifications, inflammation, cell death, into one cohesive and surprising system. The RNA binding protein I'm studying behaves like the sambal: seemingly small, but once it's in the mix, it transforms the entire dish. And just like how each bowl of laksa can be slightly different depending on the region or cook, each cell type responds to stress a bit differently—yet follows the same comforting recipe of adaptation and survival.

Peter Yeow

What appealed to you about CSI Singapore?

What CSI has achieved in the past, is advancing today, and aspires to in cancer research resonated with me. I felt my research program could both contribute to and grow with this ambitious vision.

How has the shift been from a postdoctoral fellow at Johns Hopkins Medicine to an Assistant Professor at CSI Singapore?

The transition has been both exciting and a dream come true. I still see myself as a postdoc at heart — happiest at the bench — but now with the added responsibility of leading a team. The intensity is similar, though the humidity in Singapore means I sweat a lot more!

What are you most excited to work on/working on at CSI Singapore?

I'm most excited to bring to life ideas I've been developing for some time. My lab will study weaknesses in the mitotic machinery of cancer cells and ways to target them, including TRIM E3 ligases. Being surrounded by colleagues with complementary expertise makes CSI an especially energising place to drive these ideas forward.

What's your most "this could only happen in science" moment?

Only in science do you spot people at the airport with poster tubes and instantly know they're probably off to a conference, maybe even the same one as you.

If you could name a cancer gene after a Singlish phrase, what would it be?

I'd call it "Chope." It would be a protein or complex that acts as a placeholder, holding space until the real event begins.

If your research were a hawker dish, what would it be and why?

It would be youtiao in a bowl of congee. The youtiao represents chromosomes, bundles of DNA aligned at the metaphase plate, while the bowl represents the cell. Just as youtiao must be pulled apart equally for sharing, my research explores how cells divide and how disrupting this process can selectively halt cancer growth.

4

Media Features

A) Google AI Accelerator Programme

CSI Singapore is proud to partner with Dunman Secondary School, SG Code Campus, Google Cloud, and IMDA in the *Google Cloud AI for the Biomedical Sciences* programme.

This initiative provides promising pre-university students with meaningful exposure to AI applications in real world biomedical challenges. With guidance from CSI Principal Investigators, A/Prof. Anand Jeyasekharan, Dr. Jason Pitt and their teams at CSI, students will engage with anonymized cancer imaging datasets and develop AI models using Google Cloud's advanced toolsets.

This collaboration reflects our shared commitment to nurturing future-ready talent and advancing interdisciplinary education in support of Singapore's RIE 2030 agenda.

B) Innovations That Matter - CNAxNUS Docu Series 2025 Interview with Prof. Ashok Venkitaraman

We are pleased to share that our Director, Prof. Ashok Venkitaraman, was recently featured in a Channel News Asia (CNA) documentary titled "Innovations That Matter - To Super-Aged Societies", part of the Innovations That Matter series. In this episode, Prof. Venkitaraman discusses how advances in science and medicine can support healthier ageing as societies around the world—including Singapore—grapple with the challenges of an increasingly elderly population. As a research community, it is important for us to be mindful of the implications of a super-aged society —both in terms of the opportunities it presents for scientific innovation, and the responsibility we have in shaping equitable, sustainable solutions for the future.

Read more here:



C) CSI-Next&Bio Joint Organoid Platform

The Cancer Science Institute of Singapore (CSI Singapore) has established a research collaboration with Next&Bio, an organoid-based biotechnology company, to advance organoid technologies in cancer research and precision medicine.

The collaboration was formalised at a signing ceremony in Singapore, attended by Director of CSI Singapore, Prof. Ashok Venkitaraman; CEO of Next&Bio, Park Sang-wook; and representatives from the Korea Startup Center (KSC).

Through this collaboration, CSI Singapore and Next&Bio will develop a joint organoid research platform using patient-derived organoids from diverse Asian populations in Singapore to support studies in cancer biology, drug development, and treatment response.

Next&Bio will contribute its expertise in organoid technologies to strengthen precision medicine capabilities and expand its global research footprint, while enabling engagement with pharmaceutical and clinical research stakeholders in Singapore's biomedical ecosystem.

5

Education

A. CSI Graduate Programme

The Graduate Program in Cancer Biology at CSI Singapore was established in 2010 under the National University of Singapore's Yong Loo Lin School of Medicine as part of a national effort to develop a strong pipeline of highly trained scientists in translational and multidisciplinary cancer research. The program provides a structured doctoral training within a research-intensive environment, enabling students to conduct independent, high-quality research in modern experimental and bioinformatic laboratories with access to dedicated, world-class cancer research infrastructure. In addition to close mentorship from their thesis advisors, students have opportunities to engage with the wider CSI faculty and benefit from CSI's extensive global collaboration network.

The four-year PhD program integrates formal coursework with original research leading to a doctoral thesis. A comprehensive training framework—including specialised graduate courses and professional development activities—supports students throughout and beyond their candidature, equipping them with the skills, knowledge, and experience required for research excellence. The program also actively supports students' participation in international scientific conferences, enabling meaningful engagement with the global research community and contributing to their professional development. Graduates of the program have progressed to a broad range of career pathways, including academic and research positions at leading institutions worldwide, contributing to the global cancer research ecosystem.

7
Students Admitted

107
Students Applied

57
Existing Students
27 (CSI scholars only)





L-R: Dr Priyankaa Pitcheshwar, Dr. Liu Yanjing, Dr. Roberto Magallanes

B. Alumni Stories

Dr. Priyankaa Pitcheshwar
Polly Chen's Lab , 2022 Graduate

Could you share about your career journey since completing your PhD, including how your doctoral research has shaped your current work or focus, and any professional achievements, projects, or collaborations that you are particularly proud of?

I transitioned into R&D strategy consulting after my PhD, helping biopharma and biotech clients make data-driven decisions to shape their strategy. My doctoral research trained me to think critically, challenge data, and communicate scientific insights clearly—all skills that are essential in consulting.
In this role, I've had the opportunity to work closely with C-suite and senior management teams across the industry. It has been particularly rewarding to be recognized by clients for delivering high-quality, impactful work that informs strategic decisions and drives meaningful outcomes.

Looking back, what were the most valuable skills or lessons you gained from your PhD journey?

The biggest lesson I took from my PhD was resilience. Regularly facing failed experiments taught me to troubleshoot, adapt, and persevere. This became especially important during the pandemic, helping me stay focused and complete my PhD despite challenging circumstances. Another key lesson was to be my own cheerleader. The PhD journey can be isolating, so I learned to practice self-kindness and small rituals —like treating myself to chocolate cake or a comforting meal at 'Anjappar'—which helped me recharge and maintain a positive mindset through setbacks. These lessons in perseverance and self-care have been invaluable both personally and professionally.

How did life after your PhD differ from what you expected, and what advice would you give current students preparing for that transition?

Transitioning from academia to the corporate world was a steep learning curve, with strict deadlines, fast-paced projects, collaborative work, and business jargons. While my PhD skills were highly relevant, the overall learning curve during the first six months into the job was extremely steep and enriching. For those considering consulting or other non-academic roles, I strongly recommend networking. Speaking with individuals who have made similar transitions not only demystifies the career path but also provides insights into day-to-day responsibilities, essential skills, and potential challenges, helping you evaluate whether the role aligns with your interests and career goals.

Dr. Liu Yanjing
Dan Tenen's Lab , Graduated in 2019

Could you share about your career journey since completing your PhD, including how your doctoral research has shaped your current work or focus, and any professional achievements, projects, or collaborations that you are particularly proud of?

During my PhD with Prof. Daniel Tenen at CSI, I developed CRISPR-DiR, a gene-specific demethylation tool that led to a patented technology and the discovery of Methylation Mesa, a novel class of methylation-sensitive regulatory elements linked to gene activation. This work motivated me to deepen my expertise in high-throughput functional genomics and CRISPR technology. I subsequently joined Dr. John Doench's group at the Broad Institute's Genetic Perturbation Platform, where I gained experience across multiple CRISPR modalities. I now lead the development of a genome-wide CRISPR activation platform to overcome epigenetic repression, advancing functional genomics and therapeutic discovery.

Looking back, what were the most valuable skills or lessons you gained from your PhD journey?

During my PhD, I benefited from an environment that trusted individuals to take initiative and explore ideas independently. This nurtured my self-motivation, open-mindedness, and creativity in tackling scientific questions. A strong culture of communication and collaboration built my confidence in sharing ideas, engaging scientists at all levels, and initiating collaborations. Equally influential was my PI's belief that science is a shared, intergenerational endeavour shaped by mentorship and generosity. Seeing talented researchers inspire and support one another made the journey deeply motivating. These experiences shaped my passion for science and continue to guide my commitment to fostering openness, curiosity, and mentorship in future generations.

How did life after your PhD differ from what you expected, and what advice would you give current students preparing for that transition?

I initially expected a postdoc to be a straightforward extension of my PhD, but it proved to be a far more dynamic stage. At the Broad Institute, I gained not only scientific training but also experience with large collaborative programs, academia-industry partnerships, and diverse career paths beyond traditional academia. A PhD opens many doors, from industry research to consulting, entrepreneurship, and patent law. If pursuing a postdoc, research on interested labs carefully, talk to members, and secure fellowship early. If moving beyond academia, stay curious, take initiative, and embrace adaptability — choosing your path thoughtfully and committing fully is key to success.

What's one thing you're doing now that would surprise your PhD supervisor?

My PhD supervisor might be surprised that I've transitioned from a focused approach to embracing high-throughput methodologies for both functional studies and technology innovation. Throughout my research journey, I've experienced two complementary methodological approaches: one that moves from a single point to a broader landscape, and another that goes from large-scale discovery back to specific mechanisms. Combining these approaches has expanded my scientific toolkit and perspective, enabling me to view biology from multiple angles and connect focused insight with system-level understanding.

Dr. Roberto Magallanes
Sudhakar Jha, Touati benoukraf's Lab , Graduated 2021

Could you share about your career journey since completing your PhD, including how your doctoral research has shaped your current work or focus, and any professional achievements, projects, or collaborations that you are particularly proud of?

After completing my PhD in Cancer Biology, I broadened my expertise by moving into population genomics at the Genome Institute of Singapore, where I built large-scale cloud pipelines for the National Precision Medicine Programme. My doctoral training in bioinformatics enabled a smooth transition from analysing somatic mutations in cancer to germline variation across populations. I later joined Hummingbird Bioscience, returning to cancer research and now lead the bioinformatics team supporting the full drug development pipeline. I am particularly proud of projects where my analyses directly informed clinical trial design, underscoring how academic training can translate rapidly into patient impact through industry collaboration.

Looking back, what were the most valuable skills or lessons you gained from your PhD journey?

My PhD equipped me with a strong foundation of transferable skills, including the ability to learn independently, collaborate across disciplines, and adapt quickly to new challenges. One of the most valuable lessons was learning to manage uncertainty. Research often begins without knowing whether ideas or experiments will succeed, yet still requires sustained progress within a fixed timeframe. This experience trained me to remain focused, resilient, and adaptable under ambiguity and pressure. Developing hypotheses, iterating when results were unexpected, and navigating uncertainty have been especially valuable in biotech R&D, where scientific directions, priorities, and external factors can shift rapidly.

How did life after your PhD differ from what you expected, and what advice would you give current students preparing for that transition?

Life after my PhD was more fluid and less linear than I initially expected. Rather than a single predefined path, career development involved active reflection, experimentation, and adjustment. As graduation approaches, it is helpful to think intentionally about long-term goals and to choose early roles that build relevant skills—whether toward an academic career or more industry-facing positions. It is also important to recognise when a role has served its purpose and to be open to moving on. There is no single "right" path; clarity often emerges through experience. Open conversations with mentors, peers, and professionals can be invaluable in navigating this transition.

C. Career Seminar

The career seminar held on 4 November featured three CSI alumni—Dr Priyankaa Pitcheshwar (Strategy Consultant, Catenion GmbH), Dr Liu Yanjing (Postdoctoral Researcher, Broad Institute of MIT and Harvard), and Dr Roberto Magallanes (Principal Scientist and Clinical Bioinformatics Lead, Hummingbird Bioscience)—who shared their post-graduation career journeys. The speakers provided practical guidance on preparing for academia and industry careers, navigating challenges, and leveraging useful resources for PhD training. During their visit, the alumni also reconnected with CSI Principal Investigators, strengthening alumni-faculty engagement and reinforcing long-term ties with the Institute.

6

Awards & Honours

Staff Awards

Ashok Venkitaraman
Professor
2025 class of Fellows of the American Association for Cancer Research (AACR)
Top 2% most-cited scientists 2025 (Elsevier)

Goh Boon Cher
Professor
Top 2% most-cited scientists 2025 (Elsevier/ Stanford)

Dario Campana
Professor
Top 2% most-cited scientists 2025 (Elsevier/ Stanford)

Chng Wee Joo
Professor
Top 2% most-cited scientists 2025 (Elsevier/ Stanford)

Yang Zhang
Professor
RIE 2025 Human Health & Potential (HHP) Industry Alignment Fund Pre-Positioning (IAF-PP)
Top 1% Highly Cited Researcher 2025 (Clarivate)
Top 2% most-cited scientists 2025 (Elsevier)

Anand Jeyasekharan
Assistant Professor
NMRC Clinician Scientist Award – Senior Investigator (2025)
American Association for Cancer Research (AACR) NextGen Star (2025)

Dr. David Tan
Associate Professor
Top 2% most-cited scientists 2025 (Elsevier/ Stanford)

Dr. Yvonne Tay
Associate Professor
Top 2% most-cited scientists 2025 (Elsevier/ Stanford)

Jimmy So
Professor
Top 2% most-cited scientists 2025 (Elsevier/ Stanford)

Dr. Chan Jia Jia
Senior Research Scientist
Diana Koh Fund – Young Innovator Grant

Dr. Stephen Chong
LKY Postdoctoral Fellow
Open Fund – Young Individual Research Grant
ASH Abstract Achievement Award 2025

Dr. Gan Wei Liang
Research Fellow
Diana Koh Young Innovator Prize

Dr. Jun Liu
Research Fellow
Open Fund – Young Individual Research Grant

Dr. Grishma Rane
Senior Research Scientist
Outstanding Mentor Award for Research Fellows
Diana Koh Fund – Young Innovator Grant (Main Applicant)

Dr. Tony Tan Tuan Zea
Senior Research Scientist
Top 2% most-cited scientists 2025 (Elsevier/ Stanford)

Dr. Qing Yun Tong
Research Fellow
Best Poster Award at the Asia RNA Club Symposium 2025

Dr. Madan Mohan Udaya Kumar
Research Fellow
Diana Koh Fund – Young Innovator Grant (Co-applicant)

Student Awards

Felix Blanc
PhD Candidate
Merit Award (ESMO GYN)
Merit Award (AACR/EORTC/NCI)

Rui Xue Lee
PhD Candidate
FCS 2025 Best Poster Award (AACR Travel Grant 2026)

Charmaine Ong
PhD Candidate
NCAM Best Poster Presentation (Translational Science)

Shruti Sridhar
PhD Candidate
Diana Koh Young Innovator Prize
NCAM 1st Runner Up for Oral Presentation 2025

7

Events

A. CSI Research Meeting 2025

Date	Speakers	Title
17 Jan 2025	Don Sim I PhD Student	Dissecting T cell Response in EBV-associated Nasopharyngeal Carcinoma
	Tiffanie Lim I PhD Student	Assembly Principles of Moderate Hypoxia-Induced Stress Granules
14 Feb 2025	Allen Yeoh I Associate Investigator	CAR-ing for ALL
	Arpita Datta I Research Fellow	Targeting PLK1 in HER2+ Breast Cancer (BC) Patients with Germline MET-N375S Variant: Novel Therapeutic Avenues
28 Feb 2025	Arun Kumar I Senior Research Scientist	Replication Stress and Mechanical Stress – their Connections through Topological Interface
	Jimmy So I Research Professor	Recent advances in Early Diagnosis of Gastric Cancer (GC)
7 Mar 2025	Julia Lim I Research Fellow	Glutamine Addiction of c-MAF Overexpressing Cells Drive Dysregulation of Purine Metabolism?
	Vignesh Sundararajan I Research Fellow	Loss of O-GalNAcylating Enzyme GALNT3 Expression as a Biomarker for ATR Inhibitor Sensitivity
21 Mar 2025	Roland Mate Ivanyi-Nagy I Senior Research Scientist	Proteostatic Control of the BRCA2 Tumour Suppressor by Cellular Chaperones
25 Apr 2025	Yang Zhang I Senior Principal Investigator	Deep Learning-based single- and Multi-domain Protein Structure Prediction with D-I-TASSER
	Shruti Sridhar I PhD Student	Topology of Oncogene Co-expressing Cells Determines the Microenvironment and Survival in Lymphoma

Date	Speakers	Title
9 May 2025	Haoqing Shen l Research Fellow	A Hidden Source of Immunogenic RNA in ADAR1 Deficiency
	Bibek Dutta l Research Fellow	RUNX1 Maintains Hematopoietic Stem Cell Integrity Through the Formation of Transcriptional Repressive Complex Against LINE-1 (TRCL)
23 May 2025	Govinda Lenka l Research Fellow	Midkine Expression Correlates with Bevacizumab Response and Angiogenic Activity in Nasopharyngeal Carcinoma
	Elayanambi Sundaramoorthy l Senior Research Scientist	Modulation of BRCA2 Tumour Suppression by Cellular Stress
13 Jun 2025	Hong Liang l Research Assistant	Spatial and Single-Cell Multi-omics Reveal Macrophage Heterogeneity between Primary Central Nervous System Lymphoma and Systemic Diffuse Large B-Cell Lymphoma
	Andy Wu l PhD Student	HRD-Fuse: Pancancer Prediction of Homologous Recombination Deficiency with Multiview Fusion and Contrastive Learning
20 Jun 2025	Lycia Tan l PhD Student	Elucidating ZNF143 as a Key Regulator of Liver Homeostasis and Chromatin Architecture: Implications for Liver Disease
	Don Loi Xu l PhD Student	Cancer Cell-centric Metabolism Shapes an Immunosuppressive TME by Driving the Emergence of Distinct Tumor-promoting CAF Subtypes in PDAC
4 Jul 2025	Larry Ng l Research Fellow	DDX6 Induces Immunosuppression in Cancer by Disrupting Structural Stability of Endogenous Double-stranded RNAs
	Liu Jianhua l Visiting Scholar	Germline MET N375S Variant Drives Aggressiveness in HER2-Positive Breast Cancer and Sensitizes Tumors to Combined PLK1 and HER2 Inhibition

Date	Speakers	Title
18 Jul 2025	Zi Wayne Sin l PhD Student	ZBTB48: Bridging Telomeres & Genomic Instability
	Ji Quanquan l Senior Research Scientist	Translational reprogramming following BRCA2 inactivation
1 Aug 2025	Darrel Tan l PhD Student	Investigating the Role of Long Non-coding RNAs (lncRNAs)in High Risk Multiple Myeloma
	Thuya Win Lwin l Research Fellow	Targeting PD-L1 Deglycosylation to Enhance NK Cell-Mediated Immunity in EBV-Positive Nasopharyngeal Carcinoma
15 Aug 2025	Xiaonan Fan l Research Fellow	Nanopore Direct RNA Sequencing Reveals Potential Crosstalk between 3'UTR Splicing and other RNA Processing Events in Cancer
5 Sep 2025	Jun Liu l Research Fellow	Protein-Protein Interaction, Binding Affinity, and Interface Contact Prediction Using a Pairwise Language Model
	Irfan Azaman l Research Fellow	Extracellular Vesicles Associated miR-155-5p and miR-181a-5p Promote Resistance to Daratumumab Through Downregulation of CD38
19 Sep 2025	Gan Wei Liang l Research Fellow	Understanding RNA Editing Driven Immunosuppression in Hepatocellular Carcinoma Associated Immune Cells
	Madan Mohan Udaya Kumar l Research Fellow	Transcription of the Telomeric Non-coding RNA TERRA Originates from Highly Variable Promoters
3 Oct 2025	Derrick Wee l PhD Student	Splicing of 3'UTRs May Contribute to Tumor Growth in Lung Cancer
	Stephen Chong l LKY Postdoctoral fellow	CD47-blockade Induces Necroptosis to Complement Venetoclax-induced Apoptosis in Lymphoid Malignancies
17 Oct 2025	Teoh Phaik Ju l Senior Research Scientist	Drug Tolerance in Multiple Myeloma: Novel Insights into Lenalidomide-persister Cells

B. Distinguished Speakers' Series

Prof. Hideyuki Saya
Medical Oncology ASHBi Institute for the Advanced Study of Human Biology, Kyoto University, Japan
3 March 2025,
Differential Roles of Wnt Pathway Mutations in Colorectal Cancer

Prof. Mark Dawson
Cancer Biology & Therapeutics Program, Peter MacCallum Cancer Centre, Australia
1 July 2025
Transcription Regulation and Clonal Behaviour: Understanding Epigenetic Influences on Development and Disease

Prof. Patrick Chinnery
Professor & Executive Chair UK Medical Research Council
19 June 2025,
An Evolving Symbiosis: Mitochondria in Health and Disease

Dr. Simon Boulton
Principal Group Leader, The Francis Crick Institute, UK
27 October 2025
Exploiting the 'End Replication Problem' in Cancer

C. Seminars

Dr. Mark Davis
University of Stanford, USA
24 January 2024
The Next Hundred Years of Immunology

Prof. Yasuhiro Murakawa
Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, JP
24 February 2025
Harnessing Functional Genomics to Elucidate Cancer-specific RNAs and their Regulation

Prof. Chun Kit Kwok
City University of Hong Kong, HK
5 February 2025
Mapping and Targeting of RNA G-quadruplex Structures

Prof. Andrew Hsieh
Fred Hutchinson Cancer Center, USA
10 Mar 2025
mRNA Translation in Cancer Etiology

A/Prof. Michael Birnbaum
Koch Institute for Integrative Cancer Research at MIT, USA
7 May 2025
Decoding and Rewiring Adaptive Immunity

Dr. Amit Jain
National Cancer Center Singapore, SG
14 May 2025
Establishing a Peptide-to-TCR Pipeline for Identifying Immunogenic Epitopes and Neoantigen-Specific T Cells

Dr. Sophia Wong
National Cancer Center Singapore, SG
14 May 2025
Enrichment of Next Generation Tumour-Reactive Tumour Infiltrating Lymphocytes (TILs) in Solid Cancer for Adoptive Cellular Therapy (ACT)

Prof. Sarah-Jane Dawson
Peter MacCallum Cancer Centre, AU
30 June 2025
Circulating Tumor DNA: Going Beyond the Cancer Genome

Dr. Alexia-Ileana Zaromytidou
Nature Cancer, Springer Nature
18 August 2025
Developing New CADD Methods for Drug Discovery and Relocalization

Dr. Makoto Hayashi
IFOM-KU Joint Research Laboratory IFOM ETS / Kyoto University, JP
27 August 2025
The Molecular Mechanism of Mitotic Telomere Deprotection

Prof. Michel Steinmetz
Paul Scherrer Institute (PSI), Center for Life Sciences, CH
10 September
Microtubule-mediated Signal Transduction and Interactions with Anticancer Drugs

Prof. Hans-Guido Wendel
Cancer Biology & Genetics Program
Memorial Sloan Kettering Cancer Center, USA
17 November 2025
Turning Cancer's strengths into Targetable Liabilities

D. Conferences & Symposiums

Inaugural CSI Singapore-Rogel Cancer Center Joint Symposium (1 May 2025)

On 1st May 2025, CSI Singapore and Rogel Cancer Center jointly organised their inaugural full-day scientific symposium at the University of Michigan, marking a significant milestone in the growing partnership between the two institutions. This strategic collaboration is made possible through the generous donation of Mr John Wu and Ms Jane Sun, whose support has enabled sustained scientific exchange and joint initiatives. The symposium brought together leading clinicians and scientists from both institutions for in-depth discussions across three thematic sessions—Chromosome Biology and Genome Integrity, Tumor Microenvironment, and Microbes and Metabolism. Presentations highlighted advances spanning pan-cancer genomic prediction, chromosome fragility, cancer metabolism, tumor-immune interactions, and the role of the microbiome in cancer progression and treatment response. The symposium concluded with a dedicated networking session that catalysed conversations around joint grants, trainee exchanges, and future collaborative projects. At CSI Singapore, we believe that advancing cancer research requires more than scientific excellence alone. It demands partnership - across disciplines, across institutions, and across borders. Collectively, the event reinforced a shared commitment to translational cancer research and laid a strong foundation for expanded bilateral collaborations, positioning the CSI Singapore-Rogel Cancer Center partnership for impactful discoveries in the years ahead. Building on this momentum, a second joint symposium is planned for spring 2026 to further deepen our institutional partnership and to foster enduring friendships among our researchers and students. We look forward to affirming both institutions' commitment to building a sustainable, high-impact partnership that advances cancer research through collaboration and exchange.

Back row (L-R): Bin Zhao, Eric Fearon, John Copeland
Third row (L-R): Andrzej Dlugosz, Anand Jeyasekharan, Marco Foiani, Chad Brenner, Jason Pitt
Second row (L-R): Costas Lyssiotis, Celina Kleer, Nisha D'Silva, Grace Chen, Russell Ryan
First row (L-R): Yatrik Shah, Evan Keller, Sriram Venneti

Diana Koh Learning Series 2025: Breakthroughs in Cancer (26 Jul 2025)

The Diana Koh Breakthroughs in Cancer Learning Series 2025 concluded with a powerful session of science, storytelling, and inspiration. Held at the Science Centre Singapore, the second installation of the Diana Koh Breakthroughs in Cancer Learning Series, featured talks by Prof. Goh Boon Cher, Dr. Dennis Kappei, who used relatable examples to explain complex cancer research—making the science not only informative but accessible to all. We also celebrated the future of cancer research with the Diana Koh Young Innovator Prize and the Diana Koh Young Innovator Grant. Congratulations to this year's outstanding winners, who also took the stage to present their work with the use of compelling analogies.

Catch the lectures here: https://youtu.be/3Gzo6Dpu5jI?si=Dbv6a2v4FYd6NDn1

Frontiers in Cancer Science 2025 (5-7 Nov 2025)

The 17th Frontiers in Cancer Science (FCS) conference was held in Singapore from November 5-7, 2025, at University Cultural Centre, NUS. Since its inception, FCS has grown into one of the most prominent cancer research events in the Asia-Pacific region, with over 600 delegates registered this year.

FCS 2025 attracted a diverse lineup of international and regional speakers, providing a platform for young investigators to showcase their research through posters. The conference also featured Oral Abstract Speaker sessions, where exceptional poster abstracts were selected for presentation. In addition, the two best poster presentations were awarded travel grants (worth $2,500 each) to support attendance at the AACR Annual Meeting in 2026. This marks the second consecutive year that 'Outstanding FCS Abstract Travel Awards,' were given to 10 international participants to help cover their expenses for attending FCS 2025. Awardees hailed from Australia, India, Thailand and the United States.
Since its launch in 2020, the AACR-FCS Education Sessions have been highly praised for their high participation and positive feedback. These sessions are designed to offer graduate students, post-doctoral researchers, and early-career investigators, an expanded view of contemporary cancer research. At FCS 2025, the AACR-FCS Education Sessions featured presentations from Paul Boutros (Sanford Burnham Prebys Medical Discovery Institute, United States), Daniel Durocher (Lunenfeld-Tanenbaum Research Institute, Canada), and Joanne Ngeow (NTU Lee Kong Chian School of Medicine, Singapore).

FCS 2025 was jointly organized by the CSI Singapore, Duke-NUS Medical School (Duke-NUS), Genome Institute of Singapore (GIS), Institute of Molecular and Cell Biology (IMCB), Lee Kong Chian School of Medicine (LKCMedicine), National Cancer Centre Singapore (NCCS), National University Cancer Institute, Singapore (NCIS), National Technological University of Singapore (NTU) and the Yong Loo Lin School of Medicine, NUS (YLLSoM).

CSI Singapore – Kyoto University Joint Symposium 2025 (24 - 26 Nov 2025)

The CSI Singapore - Kyoto University Joint Symposium 2025 concluded successfully after three inspiring days, held from 24 to 26 November 2025 at the National University of Singapore.

The symposium opened with welcome remarks by Prof. Tan Eng Chye, President of NUS, and Prof. Nagahiro Minato, President of Kyoto University, alongside a warm address from Prof. Ashok Venkitaraman, Director of CSI Singapore. This was followed by a distinguished keynote lecture delivered by Prof. Minato.

Across multiple scientific sessions, researchers from both institutions shared cutting-edge insights, fostering vibrant scientific dialogue and strengthening collaborative ties. Beyond the academic programme, our Kyoto University colleagues also enjoyed visits to the National Orchid Garden and shared memorable dinners with their Singapore counterparts, further deepening collegial exchange. The success of this symposium made it a meaningful platform for scientific exchange and enduring partnership.

Back row (L-R): Yasuyuki Fujita, Yasuhiro Murakawa, Hiroshi Harada, Nagahiro Minato, Ashok Venkitaraman, Chng Wee Joo, Marco Foiani, Sidonia Fagarasan, Seishi Ogawa, Polly Chen & Yvonne Tay
Front Row (L-R): Kenji Chamoto, Makoto Hayashi, Akira Yokoyama, Allen Yeoh, Peter Yeow & Zhou Yilong

L-R: Prof. Tan Eng Chye, Prof. Nagahiro Minato, Prof. Ashok Venkitaraman & Prof. Tan Eng Chye

E. Health & Wellness Talk

CSI Singapore hosted a Health & Wellness Session to support the wellbeing of our staff and students. Dr. Patrick Tan, Senior Director of the University Health Centre, kicked things off with an engaging talk on practical health and first aid tips – simple ways to stay safe and look out for one another at work. He delivered 21 bite-sized first-aid and general health tips. Participants learned to recognize common medical issues – from minor cuts and burns to bee stings and animal bites – and how to respond appropriately, including when to seek urgent care.

This was followed by a heartfelt session led by Dr. Wai Khang Yong, Facility Manager of Quantitative Proteomics Core, "Feeling Down? Who Can You Talk To?", under the Peer Staff Support Initiative, reminding us that support is always within reach. He shared practical ways peers can listen, connect, and create safe conversations around emotional wellbeing, The interactive session reinforced that while research can be demanding, no one should feel isolated, and simple knowledge and peer support can make a meaningful difference.

F. Community Engagement

Relay For Life 2025 – 100km Team Challenge (8-9 March 2025)

Eight members from CSI Singapore participated as Team CSI in the Singapore Cancer Society's Relay For Life 2025, a community movement that unites people to celebrate cancer survivors, remember loved ones lost, and fight back against cancer. As part of the 100 km Challenge Physical event, our team collectively completed 100 km over 12 hours within the iconic National Stadium, raising funds and awareness in support of cancer patients, survivors, caregivers and the broader cancer community. Through our involvement, we helped amplify the message that no one fights cancer alone and contributed to vital fundraising that supports cancer programmes and services in Singapore.



CSI at the AACR Runners for Research 5K Run/Walk, Chicago (26 April 2025)

It was a fun-filled morning at the AACR Runners for Research in Chicago on 26 April 2025, where 2 CSI members, Geraldine Leong (Outreach) and Li Si Low (Graduate Program), laced up their shoes and joined over 600 runners who showed up to brave the chilly winds and run for a cause. Despite the cold, the atmosphere was buzzing with energy as participants from all over came together in support of cancer research. We were especially thrilled that one of our very own CSI members, Li Si Low finished among the fastest in her age group – and even brought home a medal!

We're already looking forward to joining the AACR Runners for Research at the AACR Annual Meeting 2026 in San Diego!

Staff Party at Timezone (29 August 2025)

The CSI Staff Party this year brought colleagues together for an afternoon of fun and friendly competition at Timezone Orchard. Laughter, teamwork and lively arcade challenges created a relaxed setting for staff across teams to connect beyond the workplace. The event strengthened camaraderie and morale, celebrating the people who power CSI's mission while reminding us of the value of community, shared moments – and a little friendly "winning" on and off the arcade floor.

G. Core Facilities Roadshows

The 2025 CSI Core Facilities Roadshows in February and September provided a vibrant platform to showcase CSI's research infrastructure, expertise, and integrated service offerings to the wider research community. Held in high-visibility campus locations, the roadshows attracted strong engagement from researchers, students, postdoctoral fellows, principal investigators, and external partners. Interactive displays, unified branding, and game-based engagement encouraged meaningful conversations and cross-facility awareness, while several potential collaborations and follow-up leads were initiated. Overall, the roadshows reinforced CSI's commitment to enabling high-quality, collaborative research by connecting scientists with cutting-edge core facilities and expert support.



8

Publications

Publications

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Lee VGH, Loh J, Hui F, Sundar R, Tan B, Lee MC, Lin HY, Ong LC, Visvanadan N, Ow SGW, Wong ALA, Chan GHJ, Lim SE, Lim YW, Tan DSP, Ang Y, Choo J, Lee MXW, Ngoi NYL, Lee SC, Paxman R, Parker A, Lee YM, Lim JSJ.	Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers-an Asian tertiary institution experience.	Supportive Care in Cancer	32(11):762	11/1/2024	2.8	No	Wong ALA, Tan DSP,Lee SC	Co	10.1007/s00520-024-08940-2
Shao X, Yokomori R, Ong JZL, Shen H, Kappei D, Chen L, Yeoh AEJ, Tan SH, Sanda T	Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia.	Leukemia	Online ahead of print	11/2/2024	12.8	Yes	Kappei D, Chen L, Yeoh AEJ	Co	10.1038/s41375-024-02455-9
Provenzano L, Gwee YX, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao JJ, Chia DKA, Yong WP, Tan P, So J, Kim G, Shabbir A, Ong CJ, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F.	Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden.	Therapeutic Advances in Medical Oncology	16:17588359241289517.	11/4/2024	4.3	No	Yong WP, Tan P, So J	Co	10.1177/17588359241289517
Sehouli J, Boer J, Brand AH, Oza AM, O'Donnell J, Bennett K, Glaspool R, Lee CK, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O'Toole S, Lok CAR, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B, Fujiwara N, Rosengarten O, Nishio H, Kim SI, Mukopadhyay A, Piovano E, Cecere SC, Kohn EC, Mukherjee U, Nasser S, Lindemann K, Croke J, Chen X, Geissler F, Bookman MA.	How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.	Internaional Journal for Gynaecological cancer	34(11):1677-1684.	11/4/2024	4.5	No	Tan DSP	Co	10.1136/ijgc-2024-005982

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Tu Z, Bassal MA, Bell GW, Zhang Y, Hu Y, Quintana LM, Gokul D, Tenen DG, Karnoub AE.	Tumor-suppressive activities for pogo transposable element derived with KRAB domain via ribosome biogenesis restriction.	Molecular Cell	84(21):4209-4223.e6.	11/7/2024	13,9	Yes	Tenen DG	Co	10.1016/j.molcel.2024.09.025
Chong ZX, Ho WY, Yeap SK.	Deciphering the roles of non-coding RNAs in liposarcoma development: Challenges and opportunities for translational therapeutic advances	Non-coding RNA Research	11:73-90	11/15/2024	4.3	No		Co	10.1016/j.ncrna.2024.11.005
Thuya WL, Peyper JM, Myen TT, Anuar ND, Anwar A, Gudimella R, Rutt NH, Rosli NSM, Badri NH, Rahman TNA, Nurashirin R, Sethi G, Tam JKC, Wong AL, Soo R, Blackburn JM, Wang L, Goh BC.	Exosome autoantibody biomarkers for detection of lung cancer.	Military Medical Research	11(1):72	11/18/2024	16.1	Yes	Wong AL, Goh BC	Co, Last	10.1186/s40779-024-00575-y
Rane G, Kuan VLS, Wang S, Mok MMH, Khanchandani V, Hansen J, Norvaisaite I, Zulkaflee N, Yong WK, Jahn A, Mukundan VT, Shi Y, Osato M, Li F, Kappei D	ZBTB48 is a priming factor regulating B-cell-specific CIITA expression	EMBO Journal	Online ahead of print	11/19/2024	9.3	Yes	Kappei D	Last	10.1038/s44318-024-00306-y
Koh MY, Chung TH, Tang NXN, Toh SHM, Zhou J, Tan TK, Chen L, Chng WJ, Teoh PJ.	ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma.	Blood	Online ahead of print	12/9/2024	20.2	yes	Chen L, Chng WJ	Co	10.1182/blood.2024024429
Oon ML, Lim JQ, Bosch-Schips J, Climent F, Au-Yeung RKH, Hutchison B, Sohani AR, Eren OC, Kumar J, Dogan A, Ong CK, Quintanilla-Martinez L, Ng SB.	Characterizing Nodal Gamma-Delta T-Cell Lymphoma: Clinicopathological and Molecular Insights.	Modern Pathology	38(3):100685	12/14/2024	6.7	Yes	Ng SB	Last	10.1016/j.modpat.2024.100685

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Lee JY, Tan D, Ray-Coquard I, Lee JB, Kim BG, Van Nieuwenhuysen E, Huang RY, Tse KY, González-Martin A, Scott C, Hasegawa K, Wilkinson K, Yang EY, Lheureux S, Kristeleit R.	Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80).	Journal of Gynaecologic Oncology	36(1):e51	12/16/2024	3.2	No	Tan D	Co	10.3802/jgo.2025.36.e51
Gill H, Raghupathy R, Hou HA, Tsai XC, Tantiworawit A, Ooi MG, Gan GG, Wong CL, Yim RLH, Chin L, Lee P, Li VWK, Au L, Zhang Q, Leung GMK, Wu TKY, Lee YYC, Chng WJ, Tien HF, Kumana CR, Kwong YL.	Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly-diagnosed patients: impact and outcome.	Blood Advances	Online ahead of print	12/18/2024	7.6	No	Chng WJ	Co	10.1182/bloodadvances.2024014999
Cera MR, Bastianello G, Purushothaman D, Andronache A, Ascione F, Robusto M, Fagà G, Pasi M, Meroni G, Li Q, Choudhary R, Varasi M, Foiani M, Mercurio C.	A multiparametric screen uncovers FDA-approved small molecules that potentiate the nuclear mechano-dysfunctions in ATR-defective cells.	Scientific Reports	14(1):30786	12/28/2024	3.7	No	M Foiani	Co	10.1038/s41598-024-80837-w
Han MG, Maruyama S, Watanabe Y, Sawa Y, Kato D, Wake H, Reizis B, Frangos JA, Owens DM, Tenen DG, Ghiran IC, Robson SC, Fujisaki J.	Bone marrow niches orchestrate stem-cell hierarchy and immune tolerance	Nature	Online ahead of print	1/1/2025	47.7	Yes	Tenen DG	Co	10.1038/s41586-024-08352-6
Brunmeir R, Ying L, Yan J, Hee YT, Lin B, Kaur H, Leong QZ, Teo WW, Choong G, Jen WY, Koh LP, Tan LK, Chan E, Ooi M, Yang H, Chng WJ.	EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML.	Leukemia	Online ahead of print	1/7/2025	12.8	Yes	Chng WJ	Last	10.1038/s41375-024-02509-y
Chan SPY, Yeo CPX, Hong BH, Tan EMC, Beh CY, Yeo ELL, Poon DJJ, Chu PL, Soo KC, Chua MLK, Chow EK.	Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer.	Experimental Hematology & Oncology	14(1):5.	2/12/2025	12.4	Yes	Chow EK	Last	10.1186/s40164-024-00590-8

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Glaviano A, Lau HS, Carter LM, Lee EHC, Lam HY, Okina E, Tan DJJ, Tan W, Ang HL, Carbone D, Yee MY, Shanmugam MK, Huang XZ, Sethi G, Tan TZ, Lim LHK, Huang RY, Ungefroren H, Giovannetti E, Tang DG, Bruno TC, Luo P, Andersen MH, Qian BZ, Ishihara J, Radisky DC, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper KA, Shi T, Merghoub T, Krebs S, Kusumbe AP, Davids MS, Brown JR, Kumar AP.	Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.	Journal of Hematology & Oncology	18(1):6	1/13/2025	40	Yes		Co	10.1186/s13045-024-01634-6
Mitriashkin A, Yap JYY, Fernando EAK, Iyer NG, Grenci G, Fong ELS.	Cell confinement by micropatterning induces phenotypic changes in cancer-associated fibroblasts.	Acta Biomaterialia	192:61-76	1/15/2025	9.1	Yes	Fong ELS	Last	10.1016/j.actbio.2024.12.007
Wan-Qin Chong, Jia-Li Low, Joshua K Tay, Thi Bich Uyen Le, Grace Shi-Qing Goh, Kenneth Sooi, Hui-Lin Teo, Seng-Wee Cheo, Regina Tong-Xin Wong, Jens Samol, Ming-Yann Lim, Hao Li, Niranjan Shirgaonkar, Shumei Chia, Lingzhi Wang, Anil Gopinathan, Donovan Kum-Chuen Eu, Raymond King-Yin Tsang, Kwok-Seng Loh, Han-Chong Toh, Nicholas Syn, Li-Ren Kong, Ramanuj Dasgupta, Bee-Choo Tai, Yaw-Chyn Lim, Boon-Cher Goh	Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial,	The Lancet Oncology	26(2):175-186	1/15/2025	41.2	Yes	Goh BC	Last	10.1016/S1470-2045(24)00677-6
You K, Binte Mohamed Yazid N, Chong LM, Hooi L, Wang P, Zhuang I, Chua S, Lim E, Kok AZX, Marimuthu K, Vasoo S, Ng OT, Chan CEZ, Chow EK, Ho D.	Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR.	NPJ Antimicrob Resist.	3(1):12	2/21/2025	NA	NA	Chow EK	Co-Corresponding	10.1038/s44259-025-00079-2

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Luciano J. Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal, Benjamin A. Derman, Maung M. Htut, Chandramouli Nagarajan, Cesar Rodriguez, Joshua Richter, Matthew J. Frigault, Jing C. Ye, Niels W. C. J. van de Donk, Peter M. Voorhees, Benjamin Puliafito, Nizar Bahlis, Rakesh Popat, Wee Joo Chng, P. Joy Ho, Gurbakhash Kaur, Prashant Kapoor, Juan Du, Fredrik Schjesvold, Jesus Berdeja, Hermann Einsele, Adam D. Cohen, Joseph Mikhael, Yelak Biru, S. Vincent Rajkumar, Yi Lin, Thomas G. Martin & Ajai Chari	International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.	Leukemia	39, 543-554	1/27/2025	12.8	Yes	Chng WJ	Co	10.1038/s41375-024-02482-6
Fujiwara K, Nagao S, Tan D, Hasegawa K	Intraperitoneal chemotherapy is now back for ovarian cancer	International Journal of Clinical Oncology	30, 427-433 (2025)	1/29/2025	2.7	no	Tan DSP	Co	10.1007/s10147-025-02700-w
Fincham REA, Periasamy P, Joseph CR, Meng J, Lim JCT, Wee F, Stasinos K, Goulart MR, Ye J, Chong LY, Au BV, Goh D, Yeong JPS, Kocher HM.	The interplay between natural killer cells and pancreatic stellate cells in pancreatic ductal adenocarcinoma.	Cancer Commununication (Lond).	45(2):172-177.	2/1/2025	24.6	Yes	Yeong JPS	Corresponding	10.1002/cac2.12638
Liang C, Padavannil A, Zhang S, Beh S, Robinson DRL, Meisterknecht J, Cabrera-Orefice A, Koves TR, Watanabe C, Watanabe M, Illescas M, Lim R, Johnson JM, Ren S, Wu YJ, Kappei D, Ghelli AM, Funai K, Osaka H, Muoio D, Ugalde C, Wittig I, Stroud DA, Letts JA, Ho L	Formation of I2+III2 supercomplex rescues respiratory chain defects	Cell Metabolism	37(2):441-459.e11	2/4/2025	30.4	Yes	Kappei D	Co	10.1016/j.cmet.2024.11.011
Hu T, Ke X, Yu Y, Feng H, Zhang S, Cui Y, Zhang B, He M, Tang Y, Liu L, Lin Y, Ji Q, Chen C, Xu C, Hu C.	NAPTUNE: nucleic acids and protein biomarkers testing via ultra-sensitive nucleases escalation.	Nature Communications	16(1):1331	2/4/2025	14.2	Yes		Co	10.1038/s41467-025-56653-9

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Shimura M, Matsuo J, Pang S, Jangphattananont N, Hussain A, Rahmat MB, Lee JW, Douchi D, Tong JJL, Myint K, Srivastava S, Teh M, Koh V, Yong WP, So JBY, Tan P, Yeoh KG, Unno M, Chuang LSH, Ito Y	IQGAP3 signalling mediates intratumoral functional heterogeneity to enhance malignant growth	Gut	74(3):364-386	2/6/2025	25.5	yes	Yong Wp, So JB, Tan P, Ito Y	co, Last	10.1136/gutjnl-2023-330390
Koh LWH, Pang QY, Novera W, Lim SW, Chong YK, Liu J, Ang SYL, Loh RWY, Shao H, Ching J, Wang Y, Yip S, Tan P, Li S, Low DCY, Phelan A, Rosser G, Tan NS, Tang C, Ang BT.	EZH2 functional dichotomy in reactive oxygen species-stratified glioblastoma	Neuro-Oncology	27(2):398-414	2/10/2025	12.4	Yes	Tan P	Co	10.1093/neuonc/noae206
Jayagopal A, Walsh RJ, Hariprasannan KK, Mariappan R, Mahapatra D, Jaynes PW, Lim D, Peng Tan DS, Tan TZ, Pitt JJ, Jeyasekharan AD, Rajan V.	A multi-task domain-adapted model to predict chemotherapy response from mutations in recurrently altered cancer genes.	iScience.	28(3):111992	2/11/2025	4	no	JP, ADJ	Co, Corresponding	10.1016/j.isci.2025.111992
Tan YH, Yoon DH, Davies AJ, Buske C, Boo YL, Somasundaram N, Lim F, Ong SY, Jeyasekharan A, Izutsu K, Kim WS, Chan JY.	Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia.	Discover Oncology	16(1):181.	2/14/2025	2.8	no	ADJ	Co	10.1007/s12672-025-01860-5
Teo JJ, Chauhan A, Nossier R, Tan TZ, Nga VDW.	Novel treatment vs. standard of care in melanoma-associated leptomeningeal metastases: a systematic review and network meta-analysis.	Chinese Clinical Oncology	14(1):4	2/14/2025	2.4	No		Co	10.21037/cco-24-104
Sachdeva M, Blanc-Durand F, Tan D	Controversies in the management of clear cell carcinoma of the uterus and ovary	International Journal of Gynecological Cancer	35(3):101681	3/1/2025	4.5	no	Tan D	Last	10.1016/j.ijgc.2025.101681
Chong SJF, Lu J, Valentin R, Lehmberg TZ, Eu JQ, Wang J, Zhu F, Kong LR, Fernandes SM, Zhang J, Herbaux C, Goh BC, Brown JR, Niemann CU, Huber W, Zenz T, Davids MS	BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia	Molecular Cancer	24(1):62	3/3/2025	27.7	Yes	Goh BC	Co	10.1186/s12943-025-02260-7

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Chan SPY, Rashid MBMA, Lim JJ, Goh JJN, Wong WY, Hooi L, Ismail NN, Luo B, Chen BJ, Noor NFBM, Phua BXM, Villanueva A, Sam XX, Ong CJ, Chia CS, Abidin SZ, Yong MH, Kumar K, Ooi LL, Tay TKY, Woo XY, Toh TB, Yang VS, Chow EK.	Functional combinatorial precision medicine for predicting and optimizing soft tissue sarcoma treatments.	NPJ Precision Oncology	9(1):83	3/22/2025	7.9	No	Chow EK	Last	10.1038/s41698-025-00851-7
Zhu Z, Shen J, Ho PC, Hu Y, Ma Z, Wang L.	Transforming cancer treatment: integrating patient-derived organoids and CRISPR screening for precision medicine.	Frontiers in Pharmacology	16:1563198	3/25/2025	4.6	no		Co	10.3389/fphar.2025.1563198
Lim KJC, Wellard C, Moore E, Ninkovic S, Chng WJ, Spencer A, Mollee P, Hocking J, Ho PJ, Janowski W, Kim K, McCaughan G, Dun K, McQuilten ZK, Chen F, Quach H.	Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.	Clinical Lymphoma Myeloma Leukemia	25(4):243-248.	4/1/2025	2.6	No	CWJ	Co	10.1016/j.clml.2024.11.002
Wang R, Wang S, Mi Y, Huang T, Wang J, Ni J, Wang J, Yin J, Li M, Ran X, Fan S, Sun Q, Tan SY, Phillip Koeffler H, Ding L, Chen YQ, Feng N.	Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study.	British Journal of Cancer	132(6):543-557.	4/1/2025	6.7	No	Phillip Koeffler H	Co	10.1038/s41416-025-02947-0
Chan EM, Chhabra Y, Dixon KO, Durbin AD, Färkkilä A, Jeyasekharan AD, Keckesova Z, Prensner JR, Wagenblast E, Xie SZ, Zhao D.	Insights on Future Directions in Cancer Research from the 2025 AACR NextGen Stars.	Cancer Discovery	2;15(4):678-684	4/2/2025	30.3	Yes	AD J	Co	10.1158/2159-8290.CD-25-0239
Sachdeva M, Blanc-Durand F, Tan D	Controversies in the management of clear cell carcinoma of the uterus and ovary	International Journal of Gynecological Cancer	35(3):101681	3/1/2025	4.5	no	Tan D	Last	10.1016/j.ijgc.2025.101681
Chong SJF, Lu J, Valentin R, Lehmberg TZ, Eu JQ, Wang J, Zhu F, Kong LR, Fernandes SM, Zhang J, Herbaux C, Goh BC, Brown JR, Niemann CU, Huber W, Zenz T, Davids MS	BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia	Molecular Cancer	24(1):62	3/3/2025	27.7	Yes	Goh BC	Co	10.1186/s12943-025-02260-7

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Ma H, Srivastava S, Ho SWT, Xu C, Lian BSX, Ong X, Tay ST, Sheng T, Lum HYJ, Abdul Ghani SAB, Chu Y, Huang KK, Goh YT, Lee M, Hagihara T, Ng CSY, Tan ALK, Zhang Y, Ding Z, Zhu F, Ng MSW, Joseph CRC, Chen H, Li Z, Zhao JJ, Rha SY, Teh M, Yeong J, Yong WP, So JB, Sundar R, Tan P.	Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution	Cancer Discovery	15(4):767-792	4/2/2025	30.3	Yes	Yong Wp, So JB, Tan P	Co, Last	10.1158/2159-8290.CD-24-0605
Dyer M, Siu G, Thieffry D, Benoukraf T.	Leveraging the MethMotif Toolkit to Characterize Context-Specific Features and Roles of Methylation Sensitive Transcription Factors.	Current Protocols	5(4):e70129	4/5/2025	2.1	no	Benoukraf T.	Last and corresponding	10.1002/cpz1.70129
Kim K, Verburgh E, Mitina T, Chen W, Yeh SP, Schutz N, Alsharif F, Chng WJ, Huang Z, Beksac M.	Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study.	International Journal of Hematology	online ahead of print	4/15/2025	1.6	No	Chng WJ	Co	10.1007/s12185-025-03972-8
Fincham REA, Yeong JPS, Kocher HM.	Developing cell-based therapies for pancreatic ductal adenocarcinoma.	JOURNAL OF CLINICAL INVESTIGATION	135(8):e189513	4/15/2025	13.4	Yes	Yeong JPS	Co	10.1172/JCI189513
Chen Y, Davidson NM, Wan YK, Yao F, Su Y, Gamaarachchi H, Sim A, Patel H, Low HM, Hendra C, Wratten L, Hakkaart C, Sawyer C, Iakovleva V, Lee PL, Xin L, Ng HEV, Loo JM, Ong X, Ng HQA, Wang J, Koh WQC, Poon SYP, Stanojevic D, Tran HD, Lim KHE, Toh SY, Ewels PA, Ng HH, Iyer NG, Thiery A, Chng WJ, Chen L, DasGupta R, Sikic M, Chan YS, Tan BOP, Wan Y, Tam WL, Yu Q, Khor CC, Wüstefeld T, Lezhava A, Pratanwanich PN, Love MI, Goh WSS, Ng SB, Oshlack A; SG-NEx consortium; Göke J.	A systematic benchmark of Nanopore long-read RNA sequencing for transcript-level analysis in human cell lines.	Nature Methods	22(4):801-812	4/22/2025	35.1	Yes	Chng WJ, Chen L, Tan BOP, Tam WL	Co	10.1038/s41592-025-02623-4

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Teoh PJ, Koh MY, Mitsiades C, Gooding S, Chng WJ.	Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond.	Haematologica	5/1/2025	11/21/2024	8	N	CWJ	Last	10.3324/haematol.2024.285636
Dai Y, Wang P, Mishra A, You K, Zong Y, Lu WF, Chow EK, Preshaw PM, Huang D, Chew JRJ, Ho D, Sriram G.	3D Bioprinting and Artificial Intelligence-Assisted Biofabrication of Personalized Oral Soft Tissue Constructs.	Advanced Healthcare Materials	14(13):e2402727	5/1/2025	9.1	Yes	CHOW EK	Co	10.1002/adhm.202402727
Totani H, Matsumura T, Yokomori R, Umemoto T, Takihara Y, Yang C, Chua LH, Watanabe A, Sanda T, Suda T.	Mitochondria-enriched hematopoietic stem cells exhibit elevated self-renewal capabilities, thriving within the context of aged bone marrow.	Nature Aging	(5):831-847	5/5/2025	18.9	Yes	Sanda T, Suda T	Co, Last	10.1038/s43587-025-00828-y
Sridhar S, Chan ASY, Jeyasekharan AD	Single-Cell Resolved Oncogene Co-expression: From Principles to Clinical Impact.	Blood Cancer Discovery	6(4):288-292	7/1/2025	11.4	Yes	AD J	Last	10.1158/2643-3230.BCD-25-0064
Kock KH, Tan LM, Han KY, Ando Y, Jevapatarakul D, Chatterjee A, Lin QXX, Buyamin EV, Sonthalia R, Rajagopalan D, Tomofuji Y, Sankaran S, Park MS, Abe M, Chantaraamporn J, Furukawa S, Ghosh S, Inoue G, Kojima M, Kouno T, Lim J, Myouzen K, Nguantad S, Oh JM, Rayan NA, Sarkar S, Suzuki A, Thungsatianpun N, Venkatesh PN, Moody J, Nakano M, Chen Z, Tian C, Zhang Y, Tong Y, Tan CTY, Tizazu AM, Loh M, Hwang YY, Ho RC, Larbi A, Ng TP, Won HH, Wright FA, Villani AC, Park JE, Choi M, Liu B, Maitra A, Pithukpakorn M, Suktitipat B, Ishigaki K, Okada Y, Yamamoto K, Carninci P, Chambers JC, Hon CC, Matangkasombut P, Charoensawan V, Majumder PP, Shin JW, Park WY, Prabhakar S.	Asian diversity in human immune cells.	Cell	188(8):2288-2306.e24	4/17/2025	41.8	Yes	Prabhakar S.	last, lead corresponding	10.1016/j.cell.2025.02.017

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Ong JC, Zhao JJ, Liu Y, Srivastava S, Chia DKA, Quek YE, Fan X, Ma H, Huang KK, Sheng T, Tan QX, Ng G, Tan JWS, Lee JJ, Loo LH, Chong LY, Ong XW, Tay ST, Hagihara T, Tan A, Joseph CRC, Teo MCC, Hendrikson J, Chong CYL, Guo W, Chia CS, Wong JSM, Seo CJ, Cai M, Tay Y, Sim KMS, Tay RYK, Walsh R, Guaglio M, Morano F, Teh M, Lum HYJ, Lim TKH, Vermeulen L, Bijlsma MF, Lenos K, Klempner SJ, Yeong JPS, Yong WP, Pietrantonio F, Tan P, Sundar R	Spatial heterogeneity, stromal phenotypes, and therapeutic vulnerabilities in colorectal cancer peritoneal metastasis	Clinical Cancer Research	epub ahead of print	4/29/2025	10.2	Yes	Tay Y, Yong WP	Co	10.1158/1078-0432.CCR-24-3780
Liang YY, Khalid K, Le HV, Teo HMV, Raitelaitis M, Gerault MA, Lee JJH, Lyu J, Chan A, Jeyasekharan AD, Tam WL, Nordlund P, Prabhu N	MS CETSA deep functional proteomics uncovers DNA repair programs leading to gemcitabine resistance	Nature Communications	16(1):4234	5/7/2025	14.2	yes	AD J, Tam WL	Co	10.1038/s41467-025-59505-8
Wilcox JJS, Ord J, Kappei D, Gossmann TI	The CpG Landscape of Protein Coding DNA in Vertebrates	Evolutionary Applications	18(5):e70100	5/4/2025	3.3	No	Kappei D	Co	10.1111/eva.70101
Cherifi F, Ray-Coquard I, Rubio MJ, Paoletti X, Lorusso D, Choi CH, Hasegawa K, Tan DSP, Hudson E, Davis A, Tognon G, Lheureux S, Vardar Key MA, Kurtz JE, Alexandre J, Joly F	DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients	Future Oncology	1--11	5/5/2025	2.9	No	Tan D	Co	10.1080/14796694.2025.2496133
Zhong Y, Li J, Lee ARYB, Tan JYJ, Tay CJX, Koh CW, Seow EYT, Yap WC, Wong SY, Yau CE, Low CE, Tan KB, Young BE, Su Y, Devasia AG, Dharuman P, Lezhava A, Pandey R, Govindaraju PS, Yee S, Weng R, Khoo C, Tan SSY, Lee M, Lim J, Chan E, Ho CL, Chai LYA, Tan CW, Lee SC, Chan KR, Sundar R	Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination	NPJ Vaccines	10(1):90	5/9/2025	6.7	No	Lee SC	Co	10.1038/s41541-025-01141-w
Yang Li, Yang Zhang	Flexing protein assemblies	Nature Structural and Molecular Biology	Online ahead of print	5/12/2025	12.3	Yes	Yang Li(SF), Yang Zhang	First,Last	10.1038/s41594-025-01560-2

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Costa JR, Li Y, Anuar NZ, O'Connor D, Rahman S, Rapoz-D'Silva T, Fung KTM, Pocock R, Li Z, Henderson S, Wang L, Krulik ME, Hyseni S, Singh N, Morrow G, Guo Y, Gresham DOF, Herrero J, Jenner RG, Look AT, Kappei D, Mansour MR	Transcription factor cooperativity at a GATA3 tandem DNA sequence determines oncogenic enhancer-mediated activation	Cell Reports	44(5):115705	5/14/2025	7.3	No	Kappei D	Co	10.1016/j.celrep.2025.115705
Janku F, Tan DSP, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Razak A, Kan R, Reiners R, Mataraza J, Szpakowski S, Subramanian K, Chen X, Lai C, Bedard PL	First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab, in patients with advanced malignancies	ESMO Open (Science for Optimal Cancer Care)	Volume 10, Issue 6105051	5/16/2025	8.1	no	Tan DSP	Co	10.1016/j.esmoop.2025.105051
Tay RYK, Sachdeva M, Ma H, Kim YW, Kook MC, Kim H, Cheong JH, Hewitt LC, Nekolla K, Schmidt G, Yoshikawa T, Oshima T, Arai T, Srivastava S, Teh M, Ong X, Tay ST, Sheng T, Zhao JJ, Tan P, Grabsch HI, Sundar R	Spatial organization of B lymphocytes and prognosis prediction in patients with gastric cancer	Gastric Cancer	28(3):384-396	5/28/2025	4.8	no	Tan P	Co	10.1007/s10120-025-01593-y
Siu LL, Hong DS, Döcke WD, Tetzner R, Trautwein M, Phelps C, Willuda J, Yu XQ, Nogai H, Johnson M, Goh BC	A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors	Targeted Oncology	Online ahead of print	6/4/2025	3.9	No	Goh BC	Last	10.1007/s11523-025-01154-4
Anusha Amali A, Tay DJW, Seow Y, Loh M, Ravikumar S, Yu JJ, Loong SSE, Fong SW, Lee CJM, Lim JJC, Gan LH, Koh WLC, Ding Y, Sam QH, Tan Z, Tan RYM, Lua CB, Chu JJH, Singhal A, Prabhakar S, Chng WJ, Renia L, Lye DCB, Ng LFP, Tan KS, Foo R, Lee CCM, Young B, Chai LYA	Novel NUDCD1 gene variant predisposes to severe COVID-19 disease in Asians through modulation of antiviral DHX15- and MAVS-mediated signalling	Frontiers in Immunology	4;16:1581293	6/4/2025	5.5	No	Chng WJ	Co	10.3389/fimmu.2025.1581293
Yang Li, Yang Zhang	Flexing protein assemblies	Nature Structural and Molecular Biology	Online ahead of print	5/12/2025	12.3	Yes	Yang Li(SF), Yang Zhang	First,Last	10.1038/s41594-025-01560-2

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Longo MA, Ahmed SM, Chen Y, Tsai CL, Namjoshi S, Shen R, Ahmed Z, Wang X, Perera RL, Arvai A, Lee M, Kong LR, Engl W, Ng WS, Zhao ZW, Venkitaraman AR, Tainer JA, Schlacher K	BRCA2 C-terminal clamp restructures RAD51 dimers to bind B-DNA for replication fork stability	Molecular Cell	85(11):2080-2096.e6	6/5/2025	15.9	Yes	Venkitaraman AR	Corresponding	10.1016/j.molcel.2025.05.010
R Choo J, Jeraj SN, Sundar R, Yong WP, Lee M, Huang Y, Asokumaran Y, Chan GHJ, Ngoi NYL, Wong ALA, Soo RA, Chee CE, Lim JSJ, Goh BC, Lee SC, Tan DSP	NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies	Therapeutic advances in medical oncology	9;17:17588359251339930	6/9/2025	4.1	No	Yong Wp, Wong ALA, Goh BC, Lee SC, Tan DSP	Co, Last and corresponding	10.1177/17588359251339930
Blanc-Durand F, Ngoi N, Lim D, Ray-Coquard I, Tan DS	Clearer Horizons: The latest advances in clear cell ovarian cancer treatment	Cancer Treatment Reviews	Jul;138:102977	6/13/2025	10.4	Yes	Tan DS	Last and corresponding	10.1016/j.ctrv.2025.102977
Pang QY, Novera W, Koh LWH, Chong YK, Lim SW, Sim NL, Rizzetto S, Liu J, Lin X, Ang SYL, Ker JR, Wan KR, Low DCY, Cvijovic M, Goh WWB, Shao H, Tan NS, Yip S, Skanderup AMJ, Tan P, Tang C, Ang BT	Glioportal: a comprehensive transcriptomic resource unveiling ligand-mediated mesenchymal transition in glioblastoma	Neuro-oncology	Online ahead of print	6/16/2025	12.4	Yes	Skanderup, Tan P	Co	10.1093/neuonc/noaf145
Nagarajan C, Jen WY, Ooi M, De Mel S, Soekojo C, Yoon SS, Tan M, Chen Y, Li X, Pokharkar Y, Tham SN, Hashim NSB, Awasthi N, Burkill SM, Durie B, Chng WJ	A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM).	Blood Cancer Journal	17;15(1):109	6/17/2025	11	Yes	Chng WJ	Last and corresponding	10.1038/s41408-025-01296-8
Liu BH, Liu M, Radhakrishnan S, Dai MY, Jaladanki CK, Gao C, Tang JP, Kumari K, Go ML, Vu KAL, Kwon J, Seo HS, Song K, Tian X, Feng L, Tan JL, Melkonian AV, Liu Z, Wulf G, Arthanari H, Qi J, Dhe-Paganon S, Clohessy JG, Choong YK, Sivaraman J, Fan H, Tenen DG, Chai L	Targeting transcription factors through an IMiD independent zinc finger domain	EMBO Molecular Medicine	17(6):1393-1416	6/17/2025	8.3	no	Tenen DG	Co	10.1038/s44321-025-00241-3

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Chng WJ, Wu DB, Wu CK, Springford A, Daly CH, Jung SH	Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma	Clinical Lymphoma Myeloma Leukemia	25(7):e457-e465	7/1/2025	2.6	No	Chng WJ	First	10.1016/j.clml.2025.02.007
Varano G, Lonardi S, Sindaco P, Pietrini I, Morello G, Balzarini P, Vit F, Neuman H, Bertolazzi G, Brambillasca S, Parr NC, Chiarini M, Bellesi S, Maiolo E, Giampaolo S, Mainoldi F, Selvarasa V, Arima H, Pellegrini V, Pagani C, Bugatti M, Ranise C, Taddei TM, Sonoki T, Thanasi H, Morlacchi E, Segura-Garzon D, Albertini E, Daffini R, Sivacegaram A, Yang H, Li Y, Cancila V, Cicio G, Robusto M, Leuzzi B, Andronache A, Trifiro P, Riboni M, Minardi SP, Bonnal RJP, Gonzalez CL, Visco E, Capaccio P, Torretta S, Pignataro L, Almici C, Varasi M, Larocca LM, Siebert R, Falini B, Ferreri AJM, Tucci A, Lorenzini D, Cabras AD, Pruneri G, Di Napoli A, Ungari M, Pizzi M, Hohaus S, Mercurio C, Song JY, Chan WC, Lorenzi L, Bomben R, Ponzoni M, Mehr R, Tripodo C, Facchetti F, Casola S.	B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements	Blood Cancer Discovery	6(4):364-393. doi: 10.1158/2643-3230.BCD-25-0099	7/1/2025	11.4	yes		Co	10.1158/2643-3230.BCD-25-0099
Wang Y, Sun K, Li J, Guan X, Zhang O, Bagni D, Zhang Y, Carlson HA, Head-Gordon T.	A workflow to create a high-quality protein-ligand binding dataset for training, validation, and prediction tasks.	Digital Discovery	2;4(5):1209-1220	5/14/2025	5.6	No	Yang Zhang	Co	10.1039/d4dd00357h
Wu KZ, Ding RH, Zhao Z, Chong CYL, You R, Zhou H, Seah DH, Leow WQ, Lim HK, Shyamasundar S, Fernando K, Kuthubudeen FF, Ng G, Tay CY, Iyer NG, Ong CJ, Fong ELS.	Hydrogel-Mediated Preservation of Live Tumor Explants for Drug Development in Peritoneal Metastases.	Advanced Materials	e2418647	5/20/2025	25.4	Yes	Fong ELS	Last	10.1002/adma.202418647

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Zheng W, Wuyun Q, Li Y, Liu Q, Zhou X, Peng C, Zhu Y, Freddolino L, Zhang Y.	Deep-learning-based single-domain and multidomain protein structure prediction with D-I-TASSER	Nature Biotechnology	Online ahead of print	5/23/2025	41	Yes	yang Li (SF), Yang Zhang	Co-first, Last	10.1038/s41587-025-02654-4
Vogt BJ, Wang P, Chavez M, Guo P, Chow EK, Ho D, Aguado BA.	Determining sex differences in aortic valve myofibroblast responses to drug combinations identified using a digital medicine platform.	Science Advances	11(23):eadu2695.	6/6/2015	12.3	Yes	Chow EK	Co-Corresponding	10.1126/sciadv.adu2695
Phung CD, Tran TTT, Yeo BZJ, Prajogo RC, Saudjana E, Yeo EYM, Gao C, Nguyen PHD, Jayasinghe MK, Dang XTT, Lixuan CP, Nguyen TM, Peng B, Le AH, Nguyen TTT, Chan GME, Loh YH, Goh BC, Tam WL, Bonney GK, Luo D, Le MTN.	Combination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancers.	Theranostics	15(14):6818-6838	6/9/2025	13.1	Yes	Goh BC, Tam WL	Co	10.7150/thno.105519
Jue Wang, Cheng Tan, Zhangyang Gao, Guijun Zhang, Yang Zhang & Stan Z. Li	End-to-end cryo-EM complex structure determination with high accuracy and ultra-fast speed	Nature Machine Intelligence	2522-5839	6/24/2025	23.4	Yes	Yang Zhang	Corresponding	10.1038/s42256-025-01056-0
Zhang C, Freddolino L, Zhang Y.	A graphic and command line protocol for quick and accurate comparisons of protein and nucleic acid structures with US-align	Nature Protocols	Online ahead of print	7/2/2025	15.8	Yes	Yang Zhang	Last	10.1038/s41596-025-01189-x
Xiong S, Zhou J, Chng WJ	Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails	Blood	blood.2025028403	7/3/2025	22.1	Yes	Chng WJ	Last	10.1182/blood.2025028403

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Zhu Z, Kitayama J, Kim HH, So JB, Cao H, Chen L, Cheng X, Hu J, Imano M, Ishigami H, Jee YS, Kim JH, Kodera Y, Liang H, Liu X, Lu S, Mou Y, Nie M, Seo WJ, Wang Y, Wu D, Xu Z, Yamaguchi H, Yan C, Yang Z, Yin K, Yonemura Y, Yong WP, Yu J, Zhang J; Asian Gastric Cancer NIPS Treatment Collaborative Group.	Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis.	Gastric Cancer	Online ahead of print	7/14/2025	4.8	No	So JB, Yong WP	Co-first, Co	0.1007/s10120-025-01631-9
Nongyu Huang, Yang Cao, Guangjun Xiong, Suwen Chen, Juan Cheng, Yifan Zhou, Chengxin Zhang, Xiaoqiong Wei, Wenling Wu, Yawen Hu, Pei Zhou, Guolin Li, Fulei Zhao, Fanlian Zeng, Xiaoyan Wang, Jiadong Yu, Chengcheng Yue, Xinai Cui, Kaijun Cui, Huawei Cai, Yuquan Wei, Yang Zhang, Jiong Li	Evolution-guided design of mini-protein for high-contrast in vivo imaging	Acta Pharmaceutica Sinica B	Online ahead of print	7/15/2025	13.8	Yes	Yang Zhang	Corresponding	10.1016/j.apsb.2025.07.015
Blanc-Durand F, Rouleau E, Pautier P, Ngoi N, Lim YW, Lim SE, Leary A, Tan DS.	Clinical and biological characteristics associated with of loss-of-heterozygosity in endometrial cancer.	Journal of Gynecolgic Oncology	Online ahead of print	7/8/2025	3.4	No	Tan DSP	last	10.3802/jgo.2026.37.e10
Ho GF, Lee SC, Bustam AZ, Alip A, Abdul Satar NF, Saad M, Malik RA, Lim SE, Ow SGW, Wong A, Chong WQ, Ang YLE, Lee AWY, Hasan SN, Tuan Zaid N, Law KB, Toh YY, Tan HC, Selvam B, Lim J, Pan JW, Teo SH.	Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline APOBEC3B deletion: results of the phase II AUROR study.	The Lancet Regional Health-Western Pacific	60:101637	7/13/2025	7.8	Yes	LSC	Co	10.1016/j.lanwpc.2025.101637

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Cancila V, Bertolazzi G, Chan AS, Medico G, Bastianello G, Morello G, Paysan D, Lai C, Hong L, Shenoy G, Jaynes PW, Schiavoni G, Mattei F, Piconese S, Revuelta MV, Noto F, Businaro L, De Ninno A, Cammarata I, Pagni F, Venkatachalapathy S, Sangaletti S, Di Napoli A, Cicio G, Vacca D, Lonardi S, Lorenzi L, Ferreri AJ, Belmonte B, Liu M, Lakshmanan M, Ong MS, Zhang B, See T, Lam KP, Varano G, Colombo MP, Bicciato S, Inghirami G, Cerchietti L, Ponzoni M, Zappasodi R, Metzger E, Beechem J, Facchetti F, Foiani M, Casola S, Jeyasekharan AD, Tripodo C.	Aggressive B-cell lymphomas retain ATR-dependent determinants of T-cell exclusion from the Germinal Center Dark Zone	Journal of clinical Investigation	e187371	7/17/2025	13.4	Yes	Marco, ADJ	Co, Co last	10.1172/JCI187371
Phua ZY, Li M, Ali A, Cheong CCS, Goh KJ, Seto MYK, Ng ASY, Sarathy JP, Goh BC, Go ML, Chui WK, Dick T, Lam Y.	A potent phenylalkylamine disrupts mycobacterial membrane bioenergetics and augments bactericidal activity of bedaquiline.	iScience	28(7):112915	7/18/2025	4	No	GBC	Co	10.1016/j.isci.2025.112915
Sooi K, Tan TZ, Kim JW, Lee JY, Kim BG, Micklem D, Jackson A, Pinato DJ, Gourley C, Kristeleit R, Blagden SP, Bjorge L, Tan DSP.	A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.	British Journal of Cancer	Online ahead of print	7/22/2025	6.7	No	Tan DSP	Last and corresponding	10.1038/s41416-025-03090-6
Lee RX, Mohd Abdul Rashid MB, Binte Meera Sahib NR, Goh J, De Mel S, Batumalai Y, Jayalakshmi, Chua R, Poon L, Chan E, Lee J, Chee YL, Ng SB, Chan WL, Tan D, Anne CM, Nagarajan C, Chan JY, Khoo LP, Somasundaram N, Ong CK, Dachuan H, Binte Muhammad Taib NA, Chai KXY, Hooi PB, Lim ST, Chow EK, Jeyasekharan AD.	Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin's Lymphoma	JCO Precision Oncology	9:e2400780	7/23/2025	5.5	No	Ng SB, Tan D, ADJ	co, Last . Co-second author	10.1200/PO-24-00780

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Chong SJF, Lai JXH, Iskandar K, Leong BJ, Wang C, Wang Y, Guièze R, Raman D, Lim RHF, Wu CJ, Chng WJ, Cheung AMS, Chuah C, Davids MS, Pervaiz S.	Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies	Leukemia	Online ahead of print	7/24/2025	12.8	Yes	CWJ	Co	10.1038/s41375-025-02694-4
Morgan D, Zhang B, Fidan K, Pan W, Vaiyapuri TS, Raju A, Hei D, See TY, Sari IN, Chan JW, Majee P, Balachander A, Yu J, Wong AH, Mok MMH, Foo SH, Tang WL, Ang N, Tan I, Peng YF, Jaynes P, Xu S, Ghosh G, Shahabi S, Jeyasekharan AD, Ikawa M, Zhang Y, Howland SW, Lau MC, Wang VY, Lam KP, Tergaonkar V.	The transcription complex p52-ETS1 is essential for germinal center formation.	Nature Immunology	1553-1566	7/25/2025	27.2	Yes	ADJ	Co	10.1038/s41590-025-02236-1
Gill H, Yim R, Lee P, Tsai XC, Li VWK, Leung GMK, Ooi M, Hui TS, Raghupathy R, Chin L, Au L, Zhang Q, Wu TKY, Lee CYY, Chng WJ, Tien HF, Hou HA, Kwong YL.	A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia.	Blood Cancer Journal	15(1):128	7/31/2025	11	Yes	CWJ	Co	10.1038/s41408-025-01339-0
Le Minh G, Lucky SS, Pervaiz S, Ramadan K, Yeong J, Ong ST, Krishnan V, Cheok CF, Chng WJ, De Mel S, Wang X, Jeyasekharan AD, Tipgomut C, Kong LR, Sabapathy K, Chee CE, Itahana K, Taneja R, Lee SC.	Charting New Paths in Cancer Research: Insights from the Frontiers in Cancer Science Conference 2024	Cancer Research	85(15):2784-2787	8/1/2025	16.5	Yes	CWJ, ADJ, Kong LR, LSC	Co	10.1158/0008-5472.CAN-25-2205
Chen W, Cai Z, Chim CS, Chng WJ, Du J, Fu C, Gao W, Hanamura I, Hou J, Huang JS, Ishida T, Li C, Liu A, Ptushkin V, Takezako N, Wong RSM, Yoon DH.	Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.	Clinical Hematology International	7(3):36-59	8/8/2025	NA	NA	CWJ	Co	10.46989/001c.141401
Chang X, Shih CC, Chen J, Lee AS, Tan P, Wang L, Liu J, Li J, Yuan JM, Khor CC, Koh WP, Dorajoo R.	Predictive capabilities of polygenic scores in an East-Asian population-based cohort: the Singapore Chinese health study.	Communications Biology	8(1):1228	8/15/2025	5	Yes	Tan P	Co	10.1038/s42003-025-08675-8

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Rahmat MB, Hussain A, Teh YX, Dutta B, Pundrik S, Kappei D, Ito Y.	Wnt target IQGAP3 promotes Wnt signaling via disrupting Axin1-CK1α interaction	Oncogene	Online ahead of print	8/19/2025	7.2	No	DK	Co	10.1038/s41388-025-03512-y
Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva B, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Prósper F, Munshi NC.	International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.	Journal of Clinical Oncology	43(24):2739-2751	8/20/2025	42.6	Yes	CWJ	Co	10.1200/JCO-24-01893
Potts MA, Mizutani S, Deng Y, Vaidyanathan S, Ting KE, Giner G, Sridhar S, Shenoy G, Liao Y, Diepstraten ST, Kueh AJ, Pal M, Healey G, Tai L, Wang Z, König C, Kaloni D, Whelan L, Milevskiy MJG, Coughlan HD, Pomilio G, Wei AH, Visvader JE, Papenfuss AT, Wilcox S, Jeyasekharan AD, Shi W, Lelliott EJ, Kelly GL, Brown KK, Strasser A, Herold MJ.	Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma.	Nature Communications	16(1):7582	8/21/2025	15.2	Yes	ADJ	Co	10.1038/s41467-025-62615-y
Wong ETY, Liew IT, Than H, Ho AYL, Nagarajan C, Goh YT, Chuah CTH, Poon ML, Chng WJ, Ooi MGM, De Mel WSP, Yeo AEJ, Kee T, Vathsala A.	Deceased donor kidney transplantation in candidates with pre-transplant hematological malignancies: a literature review and recipient allocation proposal in Singapore.	Journal of Nephrology	Online ahead of print	8/22/2025	2.5	No	CWJ	Co	10.1007/s40620-025-02381-8
Sim TM, Chng WJ, Liu H, de Mel S	Targeting the CD47-SIRPalpha checkpoint in multiple myeloma.	Discover Oncology	16(1):1616	8/25/2025	2.8	No	CWJ	Co	10.1007/s12672-025-03312-6

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Wang Y, Zhang L, Wang LZ, Cao Y, Huang L, Sethi G, Chen X, Wang L, Goh BC.	The application of organoids in treatment decision-making for digestive system cancers: progress and challenges	Molecular Cancer	24(1):222	8/25/2025	27.7	yes	GBC	co	10.1186/s12943-025-02429-0
Deka K, Carter JM, Bahai A, Ang DA, Sim N, Chong HY, Lee GHB, Tan SM, Chng WJ, Kappei D, Li Y.	Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation	Nature Communications	16(1):8155	9/1/2025	15.2	Yes	CWJ, DK	Co	10.1038/s41467-025-63256-x
Chin KW, Chong WQ, Goh BC, Ma BBY.	Evolving landscape of nasopharyngeal carcinoma therapy.	Nature Cancer	6(9):1480-1482	9/6/2025	33.3	Yes	GBC	Co	10.1038/s43018-025-01045-7
Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N.	A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).	International Gynaecological Cancer	online ahead ofprint	9/7/2025	NA	NA	Tan DSP	Co	10.1016/j.ijgc.2025.102654
Ngoi NYL, Choi CH, Zhu J, Lim D, Tan TZ, Sun H, Heong V, Ow SGW, Chay WY, Kim HS, Lim YW, Lim SE, Goss G, Goh JC, Kim JW, Friedlander M, Tai BC, Kim K, Tan DSP.	Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.	Clinical cancer research	31(18):3907-3915	9/15/2025	10	Yes	Tan DSP	last	10.1158/1078-0432.CCR-25-0201
Khong A, Ripin N, de Vasconcelos LM, Passanisi V, Spencer S, Parker R.	Stress granules promote quiescence by enhancing p21 levels and reducing phospho-Rb	RNA	31(10):1472-1487	9/16/2025	4.8	No	AK	First and Corresponding	10.1261/rna.080635.125

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Zhou Y, Shvedunova M, Akhtar A.	Protocol to isolate stress granules in HeLa cells using fluorescence-activated non-membrane condensate isolation.	STAR Protoc.	6(3):103987.	9/19/2025	1.3	No	Zhou Y	First and Corresponding	10.1016/j.xpro.2025.103987
Abu-Remaileh M, Chan CJ, Chen L, Demirer GS, Fiszbein A, Jug F, Lechuga-Vieco AV, Luisier R, Pagan J, Sabari BR, Shao S, Sun L, Żylicz JJ	Visions of the future of molecular cell biology	Nature Reviews. Molecular Cell Biology	26(10):735-740.	9/22/2025	89.6	Yes	PLC	Corresponding	10.1038/s41580-025-00892-7
Thuya WL, Cao Y, Ho PC, Wong AL, Wang L, Zhou J, Nicot C, Goh BC	Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy	Cytokine and Growth Factor Reviews	85:26-42	10/1/2025	11.7	No	GBC	Co	10.1016/j.cytogfr.2025.01.003
Quek AML, Teng O, Park JH, Goh JY, Tan TZ, Er BGC, Ng GJL, Lim ECH, Halliwell B, Seet RCS.	Elevated uric acid and impaired triglyceride metabolism predict mortality in women after ischemic stroke.	Free Radical Biology & Medicine	238:542-549.	10/1/2025	7.9	Yes		Co	10.1016/j.freeradbiomed.2025.07.015
Kim JS, Song Y, Jen WY, Chim CS, Lee JJ, Yoon SS, Ng SC, Gan GG, Handa H, Lee JH, Kim K, Ito S, Huang JS, Min CK, Ooi Gaik Ming M, de Mel S, Soekojo C, Li X, Awasthi N, Pokharkar Y, Durie BG, Chng WJ.	Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)	Blood Cancer Journal	15(1):155	10/6/2025	11	Yes	CWJ	Last	10.1038/s41408-025-01356-z
Chan JY, Fujimoto A, Chang EWY, Gan GG, Tan SM, Ng SC, Chang KM, Caguioa P, Datukan J, Hong H, Chuncharunee S, Nga DH, Sutandyo N, Ong CK, Poon ML, Jeyasekharan A, Somasundaram N, Lunning M, Suzuki R, Izutsu K, Tse E, Lim ST, Kim WS.	Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.	JCO Global Oncology	e2500353	10/11/2025	3.0	No	ADJ	Co	10.1200/GO-25-00353

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Huang C, Gao Y, Chen J, Hong JH, Jiang Y, Chai KXY, Li Y, Wang P, Wang Y, Gao J, Zeng X, Xiao R, He H, Guan P, Chan JY, Lim JQ, Jeyasekharan AD, Dachuan H, Bei JX, Teh BT, Lim ST, Yu Q, Ong CK, Huang H, Tan J.	Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphom	Cancer Discover	online ahead ofprint	10/15/2025	32.8	Yes	ADJ	Co	10.1158/2159-8290.CD-25-0587
Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, Fang Y, Lu S, Dong X, Wu L, Shinno Y, Daniele G, Yang TY, Kim HR, Ruiter G, Zhao J, Novello S, Miao L, Jänne PA, Goto K, Rüttinger D, Descamps T, Brase JC, Bao W, Li R, Brega N, Grassi P, Girard N, Tan DS; SOHO-01 Investigators.	Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer	New England Journal of Medicine	online ahead ofprint	10/17/2025	77.9	Yes	GBC	Co	10.1056/NEJMoa2511065
Chan WL, Hue SS, Deng L, Leong SM, Chng WJ, Ng SB.	Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications.	The Lancet. The Lancet Regional Health-Western Pacific	62:101550	9/14/2025	7.8	Yes	CWJ, Ng SB	CWJ : Corresponding. Ng SB: Corresponding, last author)	10.1016/j.lanwpc.2025.101550
Kumari N, Wright SC, Witham CM, Monserrat L, Palafox M, Richard JL, Costa C, Elkabets M, Agostino M, Klemm T, Eccles M, Garnham A, Wu T, Nilsson JA, Walz N, Venugopal V, Cerra A, Vasilevski N, Bridgeman S, Bassi S, Saei A, Helal M, Neundorf P, Riedel A, Rosenfeldt M, Gill J, Pahor N, Hartmann O, Chung J, Sidhu SS, Moderau N, Jha S, Rodon J, Diefenbacher ME, Komander D, Serra V, Eichhorn PJA.	USP10/GSK3β-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer	JOURNAL OF CLINICAL INVESTIGATION	135(22):e180927	9/23/2025	13.4	Yes		First	10.1172/JCI180927
Yu X, Huang C, Evers M, Liu J, Ting HJ, Zhang S, Chong SY, Tan MS, Wang S, Sayed N, Gao L, Muthiah MD, Soon GST, Wee A, Chow EK, Soh NJH, Pastorin G, Yu VC, Liu B, Dan YY, Torta F, Schiffelers R, Storm G, Wang JW	Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH	Science Advances	11(39):eadx2681	9/26/2025	12.3	Yes	Ed Chow, Dan YY	Co	10.1126/sciadv.adx2681

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Yu X, Huang C, Evers M, Liu J, Ting HJ, Zhang S, Chong SY, Tan MS, Wang S, Sayed N, Gao L, Muthiah MD, Soon GST, Wee A, Chow EK, Soh NJH, Pastorin G, Yu VC, Liu B, Dan YY, Torta F, Schiffelers R, Storm G, Wang JW	Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH	Science Advances	11(39):eadx2681	9/26/2025	12.3	Yes	Ed Chow, Dan YY	Co	10.1126/sciadv.adx2681
Ichimasa K, Kudo SE, Kouyama Y, Takashina Y, Chung H, Maeda Y, Lwin WP, Toya Y, Hatta W, So JBY, Yeoh KG, Nemoto T, Misawa M.	Artificial Intelligence-Assisted Whole Slide Image Analysis for Lymph Node Status Prediction in Early Colorectal and Gastric Cancer.	Digestive Endoscopy	online ahead of print	9/27/2025	4,2	No	So JBY	Co	10.1111/den.70042
Gan WL, Chen L.	A-to-I RNA editing in hematologic immunity and malignancy	Experimental Hematology	150:104861	10/1/2025	1.9	no	Chen L	Last	10.1016/j.exphem.2025.104861
Samy A, Tham CY, Dyer M, Benoukraf T.	NanoVar: a comprehensive workflow for structural variant detection to uncover the genome's hidden patterns	Nature Protocols	Online ahead of print.	10/1/2025	15.8	Yes	Benoukraf	Last	10.1038/s41596-025-01270-5
Yap TA, Tan DSP, Stathis A, Shapiro GI, Iwasa S, Joerger M, Zhang J, Plummer R, Sawyer MB, Tan DSW, Castonguay V, Gabrail NY, Matsubara N, Wilkinson G, Ludwig M, Schlicker A, Zhou Y, Merz C, Däbritz JHM, Jeffers M, Hreiki J, de Bono JS	Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects	Cancer Discovery	15(10):2019-2035	10/6/2025	30.3	Yes	DSP	Co	10.1158/2159-8290.CD-24-1500
Soekojo C, Chung SJ, Tsai MT, Chen W, Huang J, Kim JS, Lee DG, Min CK, Suzuki K, Swaminathan S, Takamatsu H, Tan D, Yanamandra U, Nagarajan C, Chng WJ.	Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma-Experience from Asian Countries	Clinical lymphoma, myeloma & leukemia	online ahead of print	10/11/2025	2.6	No	CWJ	Last	10.1016/j.clml.2025.10.005

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Poh XY, Loh FK, Bai C, Chong HT, Teo WK, Wong YH, Hong JM, Miow QH, Thong PM, Vilaysane B, Hu TH, Chhabra S, Wang Y, Tiong SC, Fong SM, Kamihigashi M, Rajarethinam R, Looi WD, Cheow ESH, Bonney GK, Pakkiri LS, Drum CL, Peng YF, Lee M, Tan CL, Ding CSL, Lim TCC, Yeo TW, Tay JK, Vallejo AF, Ong CWM.	MMPs and NETs are detrimental in CNS-tuberculosis with MMP Inhibition in CNS-tuberculosis mice improving survival.	Journal of Neuroinflammation	22(1):230	10/11/2025	9.8	Yes		Co	10.1186/s12974-025-03548-7
Hirade K, Tanaka N, Kajino T, Adachi Y, Kimura R, Kasuya H, Kisoda S, Tan TK, Hayakawa S, Sato T, Yanase S, Kitaura Y, Yamamoto T, Nishioka Y, Muto O, Muraoka D, Fujishita T, Kasuga N, Watanabe K, Sakata Y, Aoki M, Matsushita H, Sanda T, Iida S, Tsuchiya K, Yamaguchi R, Ebi H.	Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy.	Cell Reports Medicine	6(9):102317.	9/16/2025	10.5	no	Sanda T	Co	10.1016/j.xcrm.2025.102317
Nah GSS, Matsuo J, Bahirvani AG, Kimura S, Chin DWL, Ng KP, Koh CP, Mok MMH, Wang CQ, Tergaonker V, Voon DC, Kohu K, Muroi S, Shi J, Yu S, Hossain MZ, Liau WS, Phuong CTN, Sanda T, Marsman J, Horsfield J, Cheroutre H, Chan YH, Pang B, Chong PY, Soong R, Tenen DG, Maekawa Y, Venkatesh B, Ito Y, Taniuchi I, Osato M.	An Upstream RUNX3 Enhancer, eR3 (-18m/-28h), Regulates the Development of Gut-Associated Anti-Tumorigenic CD8+CD103+ Cytotoxic T Lymphocytes in Mouse and Human. Genes Cells.	Genes to Cells	30(6):e70052	10/19/2025	1.2	No	Sanda T, Tenen DG, Ito	Co	10.1111/gtc.70052
Wu KZ, Zeng B, Seah DH, Ng IZR, Ding RH, Zhang T, Kalaichelvan M, You R, Fong ELS.	Advances in In Vitro Modeling of Cancer-Stromal Interactions: From Fundamental Insights to Translational Applications.	Advanced Materials	online ahead of print	10/21/2025	25.4	Yes	Fong ELS	Last	10.1002/adma.202512252
Quek AML, Teng O, Tan TZ, Park JH, Er BGC, Goh JY, Jing M, Tan BYQ, Yeo LY, Chan BPL, Teoh HL, Oh VMS, Lim ECH, Seet RCS.	Accelerated Aging Predicts Earlier Onset of Ischemic Stroke: A Proteomic and Transcriptomic Investigation.	European Journal of Preventive Cardiology	zwaf691	10/27/2025	6.8	Yes		Co	10.1093/eurjpc/zwaf691

Authors	Title	Journal	Vol/Page	Date	Impact Factor	Top 10% of Journals	PI	Authorship	doi
Sheng T, Sundar R, Srivastava S, Ong X, Tay ST, Ma H, Uchihara T, Lian BSX, Hagihara T, Kong MS, Xu C, Ho SWT, Huang KK, Tan ALK, Ng MSW, Toh J, Ng CSY, Nasca V, Pircher CC, Randon G, Giordano S, Corso S, Lum JHY, Zhao JJ, Teh M, So JBY, Sabella G, Prabhakar S, Lee J, Ng MCH, Shitara K, Gasparello J, Fassan M, Pietrantonio F, Tan P.	Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy.	Gut	online ahead of print	10/30/2025	25.5	Yes	So JBY	Co	10.1136/gutjnl-2024-334667
Wu Z, Wang Z, Ng SQ, Lidster JA, Schwerd-Kleine P, Phua ZJC, Peh KLE, Ho YY, Yuan J, Shathishwaran S, Yeo XH, Zhang Y, Chiu YHJ, Lau LYE, Lim TKH, Takano A, Tan EH, Skanderup AJ, Tergaonkar V, Han W, Ho YS, Tan DSW, Tam WL.	Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancer.	Cell Metabolism	37(11):2233-2249.e9.	11/4/2025	30.4	Yes	TWL	Last	10.1016/j.cmet.2025.10.001
Prawira A, Xu H, Mei Y, Leow WQ, Nasir NJM, Reolo MJ, Otsuka M, Rahbari M, Chen Z, Weerasooriya M, Abdullah LB, Wu J, Hazirah SN, Wasser M, Chung A, Goh BK, Chow PK, Albani S, Lee J, Lim TKH, Zhai W, Dan YY, Goh GB, Heikenwälder MF, Zhang Y, Dasgupta R, Tai WMD, Liu H, Chen J, Chew V.	Targeting Treg-fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma.	Gut	online ahead of print	11/5/2025	25.5	Yes	Dan YY	Co	10.1136/gutjnl-2025-335084
Lee SC, Lucky SS, Zhu J, Ow S, Loh L, Tan JH, Lim SE, Hairom Z, Mehta S, Tai BC, Goh BC.	Pragmatic Interventions to Boost Surveillance Mammogram Uptake Among an Overdue Population: A Randomized Clinical Trial	JAMA Internal Medicine	online ahead of print	11/10/2025	22.7	Yes	LSC, GBC	First, Last	10.1001/jamainternmed.2025.5873
Ber S, Yang M, Sciacovelli M, Samarajiwa S, Patel K, Nikitopoulou E, Howitt A, Cook SJ, Venkitaraman AR, Frezza C, Esposito A.	FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer.	EMBO Reports	online ahead of print	11/20/2015	6.1	no	AV	Co	10.1038/s44319-025-00641-z
Qiao X, Yang X, Diao Y, Li Q, Wang X, Li C, Yang Z, Chng WJ, Li B.	USP13 dictates Ran turnover and vulnerability to ferroptosis in diffuse large B cell lymphoma (DLBCL).	Cell Death and Disease	16(1):870.	11/28/2025	9.4	no	Chng WJ	Co, Co-Corresponding	10.1038/s41419-025-08207-6